,Change_Type,Covered_Recipient_Type,Noncovered_Recipient_Entity_Name,Teaching_Hospital_CCN,Teaching_Hospital_ID,Teaching_Hospital_Name,Covered_Recipient_Profile_ID,Covered_Recipient_NPI,Covered_Recipient_First_Name,Covered_Recipient_Middle_Name,Covered_Recipient_Last_Name,Covered_Recipient_Name_Suffix,Recipient_Primary_Business_Street_Address_Line1,Recipient_Primary_Business_Street_Address_Line2,Recipient_City,Recipient_State,Recipient_Zip_Code,Recipient_Country,Recipient_Province,Recipient_Postal_Code,Covered_Recipient_Primary_Type_1,Covered_Recipient_Primary_Type_2,Covered_Recipient_Primary_Type_3,Covered_Recipient_Primary_Type_4,Covered_Recipient_Primary_Type_5,Covered_Recipient_Primary_Type_6,Covered_Recipient_Specialty_1,Covered_Recipient_Specialty_2,Covered_Recipient_Specialty_3,Covered_Recipient_Specialty_4,Covered_Recipient_Specialty_5,Covered_Recipient_Specialty_6,Covered_Recipient_License_State_code1,Covered_Recipient_License_State_code2,Covered_Recipient_License_State_code3,Covered_Recipient_License_State_code4,Covered_Recipient_License_State_code5,Principal_Investigator_1_Covered_Recipient_Type,Principal_Investigator_1_Profile_ID,Principal_Investigator_1_NPI,Principal_Investigator_1_First_Name,Principal_Investigator_1_Middle_Name,Principal_Investigator_1_Last_Name,Principal_Investigator_1_Name_Suffix,Principal_Investigator_1_Business_Street_Address_Line1,Principal_Investigator_1_Business_Street_Address_Line2,Principal_Investigator_1_City,Principal_Investigator_1_State,Principal_Investigator_1_Zip_Code,Principal_Investigator_1_Country,Principal_Investigator_1_Province,Principal_Investigator_1_Postal_Code,Principal_Investigator_1_Primary_Type_1,Principal_Investigator_1_Primary_Type_2,Principal_Investigator_1_Primary_Type_3,Principal_Investigator_1_Primary_Type_4,Principal_Investigator_1_Primary_Type_5,Principal_Investigator_1_Primary_Type_6,Principal_Investigator_1_Specialty_1,Principal_Investigator_1_Specialty_2,Principal_Investigator_1_Specialty_3,Principal_Investigator_1_Specialty_4,Principal_Investigator_1_Specialty_5,Principal_Investigator_1_Specialty_6,Principal_Investigator_1_License_State_code1,Principal_Investigator_1_License_State_code2,Principal_Investigator_1_License_State_code3,Principal_Investigator_1_License_State_code4,Principal_Investigator_1_License_State_code5,Principal_Investigator_2_Covered_Recipient_Type,Principal_Investigator_2_Profile_ID,Principal_Investigator_2_NPI,Principal_Investigator_2_First_Name,Principal_Investigator_2_Middle_Name,Principal_Investigator_2_Last_Name,Principal_Investigator_2_Name_Suffix,Principal_Investigator_2_Business_Street_Address_Line1,Principal_Investigator_2_Business_Street_Address_Line2,Principal_Investigator_2_City,Principal_Investigator_2_State,Principal_Investigator_2_Zip_Code,Principal_Investigator_2_Country,Principal_Investigator_2_Province,Principal_Investigator_2_Postal_Code,Principal_Investigator_2_Primary_Type_1,Principal_Investigator_2_Primary_Type_2,Principal_Investigator_2_Primary_Type_3,Principal_Investigator_2_Primary_Type_4,Principal_Investigator_2_Primary_Type_5,Principal_Investigator_2_Primary_Type_6,Principal_Investigator_2_Specialty_1,Principal_Investigator_2_Specialty_2,Principal_Investigator_2_Specialty_3,Principal_Investigator_2_Specialty_4,Principal_Investigator_2_Specialty_5,Principal_Investigator_2_Specialty_6,Principal_Investigator_2_License_State_code1,Principal_Investigator_2_License_State_code2,Principal_Investigator_2_License_State_code3,Principal_Investigator_2_License_State_code4,Principal_Investigator_2_License_State_code5,Principal_Investigator_3_Covered_Recipient_Type,Principal_Investigator_3_Profile_ID,Principal_Investigator_3_NPI,Principal_Investigator_3_First_Name,Principal_Investigator_3_Middle_Name,Principal_Investigator_3_Last_Name,Principal_Investigator_3_Name_Suffix,Principal_Investigator_3_Business_Street_Address_Line1,Principal_Investigator_3_Business_Street_Address_Line2,Principal_Investigator_3_City,Principal_Investigator_3_State,Principal_Investigator_3_Zip_Code,Principal_Investigator_3_Country,Principal_Investigator_3_Province,Principal_Investigator_3_Postal_Code,Principal_Investigator_3_Primary_Type_1,Principal_Investigator_3_Primary_Type_2,Principal_Investigator_3_Primary_Type_3,Principal_Investigator_3_Primary_Type_4,Principal_Investigator_3_Primary_Type_5,Principal_Investigator_3_Primary_Type_6,Principal_Investigator_3_Specialty_1,Principal_Investigator_3_Specialty_2,Principal_Investigator_3_Specialty_3,Principal_Investigator_3_Specialty_4,Principal_Investigator_3_Specialty_5,Principal_Investigator_3_Specialty_6,Principal_Investigator_3_License_State_code1,Principal_Investigator_3_License_State_code2,Principal_Investigator_3_License_State_code3,Principal_Investigator_3_License_State_code4,Principal_Investigator_3_License_State_code5,Principal_Investigator_4_Covered_Recipient_Type,Principal_Investigator_4_Profile_ID,Principal_Investigator_4_NPI,Principal_Investigator_4_First_Name,Principal_Investigator_4_Middle_Name,Principal_Investigator_4_Last_Name,Principal_Investigator_4_Name_Suffix,Principal_Investigator_4_Business_Street_Address_Line1,Principal_Investigator_4_Business_Street_Address_Line2,Principal_Investigator_4_City,Principal_Investigator_4_State,Principal_Investigator_4_Zip_Code,Principal_Investigator_4_Country,Principal_Investigator_4_Province,Principal_Investigator_4_Postal_Code,Principal_Investigator_4_Primary_Type_1,Principal_Investigator_4_Primary_Type_2,Principal_Investigator_4_Primary_Type_3,Principal_Investigator_4_Primary_Type_4,Principal_Investigator_4_Primary_Type_5,Principal_Investigator_4_Primary_Type_6,Principal_Investigator_4_Specialty_1,Principal_Investigator_4_Specialty_2,Principal_Investigator_4_Specialty_3,Principal_Investigator_4_Specialty_4,Principal_Investigator_4_Specialty_5,Principal_Investigator_4_Specialty_6,Principal_Investigator_4_License_State_code1,Principal_Investigator_4_License_State_code2,Principal_Investigator_4_License_State_code3,Principal_Investigator_4_License_State_code4,Principal_Investigator_4_License_State_code5,Principal_Investigator_5_Covered_Recipient_Type,Principal_Investigator_5_Profile_ID,Principal_Investigator_5_NPI,Principal_Investigator_5_First_Name,Principal_Investigator_5_Middle_Name,Principal_Investigator_5_Last_Name,Principal_Investigator_5_Name_Suffix,Principal_Investigator_5_Business_Street_Address_Line1,Principal_Investigator_5_Business_Street_Address_Line2,Principal_Investigator_5_City,Principal_Investigator_5_State,Principal_Investigator_5_Zip_Code,Principal_Investigator_5_Country,Principal_Investigator_5_Province,Principal_Investigator_5_Postal_Code,Principal_Investigator_5_Primary_Type_1,Principal_Investigator_5_Primary_Type_2,Principal_Investigator_5_Primary_Type_3,Principal_Investigator_5_Primary_Type_4,Principal_Investigator_5_Primary_Type_5,Principal_Investigator_5_Primary_Type_6,Principal_Investigator_5_Specialty_1,Principal_Investigator_5_Specialty_2,Principal_Investigator_5_Specialty_3,Principal_Investigator_5_Specialty_4,Principal_Investigator_5_Specialty_5,Principal_Investigator_5_Specialty_6,Principal_Investigator_5_License_State_code1,Principal_Investigator_5_License_State_code2,Principal_Investigator_5_License_State_code3,Principal_Investigator_5_License_State_code4,Principal_Investigator_5_License_State_code5,Submitting_Applicable_Manufacturer_or_Applicable_GPO_Name,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Country,Related_Product_Indicator,Covered_or_Noncovered_Indicator_1,Indicate_Drug_or_Biological_or_Device_or_Medical_Supply_1,Product_Category_or_Therapeutic_Area_1,Name_of_Drug_or_Biological_or_Device_or_Medical_Supply_1,Associated_Drug_or_Biological_NDC_1,Associated_Device_or_Medical_Supply_PDI_1,Covered_or_Noncovered_Indicator_2,Indicate_Drug_or_Biological_or_Device_or_Medical_Supply_2,Product_Category_or_Therapeutic_Area_2,Name_of_Drug_or_Biological_or_Device_or_Medical_Supply_2,Associated_Drug_or_Biological_NDC_2,Associated_Device_or_Medical_Supply_PDI_2,Covered_or_Noncovered_Indicator_3,Indicate_Drug_or_Biological_or_Device_or_Medical_Supply_3,Product_Category_or_Therapeutic_Area_3,Name_of_Drug_or_Biological_or_Device_or_Medical_Supply_3,Associated_Drug_or_Biological_NDC_3,Associated_Device_or_Medical_Supply_PDI_3,Covered_or_Noncovered_Indicator_4,Indicate_Drug_or_Biological_or_Device_or_Medical_Supply_4,Product_Category_or_Therapeutic_Area_4,Name_of_Drug_or_Biological_or_Device_or_Medical_Supply_4,Associated_Drug_or_Biological_NDC_4,Associated_Device_or_Medical_Supply_PDI_4,Covered_or_Noncovered_Indicator_5,Indicate_Drug_or_Biological_or_Device_or_Medical_Supply_5,Product_Category_or_Therapeutic_Area_5,Name_of_Drug_or_Biological_or_Device_or_Medical_Supply_5,Associated_Drug_or_Biological_NDC_5,Associated_Device_or_Medical_Supply_PDI_5,Total_Amount_of_Payment_USDollars,Date_of_Payment,Form_of_Payment_or_Transfer_of_Value,Expenditure_Category1,Expenditure_Category2,Expenditure_Category3,Expenditure_Category4,Expenditure_Category5,Expenditure_Category6,Preclinical_Research_Indicator,Delay_in_Publication_Indicator,Name_of_Study,Dispute_Status_for_Publication,Record_ID,Program_Year,Payment_Publication_Date,ClinicalTrials_Gov_Identifier,Research_Information_Link,Context_of_Research
4206,UNCHANGED,Covered Recipient Teaching Hospital,,500008.0,11198.0,UNIVERSITY OF WASHINGTON MED CTR,,,,,,,1959 Ne Pacific St,,Seattle,WA,98195,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,120705.0,1659512895.0,CHARLES,S,LANDIS,,UNIVERSITY OF WASHINGTON MEDICAL CENTER,1959 NE PACIFIC DIVISION OF HEPATOLOGY,SEATTLE,WA,98195-2401,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology,,,,,,NY,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Allergan, Inc.",100000000278,"Allergan, Inc.",NJ,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1078.25,03/17/2021,Cash or cash equivalent,,,,,,,No,No,"AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis",No,789026061,2021,01/20/2023,,,3152-301-002
3734,UNCHANGED,Covered Recipient Teaching Hospital,,464009.0,11166.0,U OF UTAH NEUROPSYCHIATRIC INSTITUTE,,,,,,,50 N Medical Dr,,Salt Lake City,UT,84132,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1042095.0,1831340231.0,RAZA,A,PATEL,,81 N MARIO CAPECCHI DR,,SALT LAKE CITY,UT,84113-1125,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pediatrics|Pediatric Gastroenterology,,,,,,UT,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Allergan, Inc.",100000000278,"Allergan, Inc.",NJ,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2150.0,08/01/2021,Cash or cash equivalent,,,,,,,No,No,?Pediatric (12-17) Clinical Pharmacology/Efficacy/Safety Study,No,789021111,2021,01/20/2023,,,3030-202-002
4102,UNCHANGED,Covered Recipient Teaching Hospital,,490009.0,10745.0,University Of Virginia Medical Cente,,,,,,,1215 LEE ST PFS,,CHARLOTTESVILLE,VA,22908,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,767059.0,1174812010.0,MICHAEL,E.,DEVITT,,590 Peter Jefferson Pkwy,,CHARLOTTESVILLE,VA,22911,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine,,,,,,VA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Seagen Inc.,100000000279,Seagen Inc.,WA,United States,Yes,Covered,Biological,Oncology,PADCEV,51144-030-01,,,,,,,,,,,,,,,,,,,,,,,,,,23016.0,09/07/2021,In-kind items and services,,,,,,,No,No,"Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without Chemotherapy, Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer",No,792665001,2021,01/20/2023,NCT04223856,https://clinicaltrials.gov/ct2/show/NCT04223856,"This study is being conducted to evaluate the combination of enfortumab vedotin + pembrolizumab, with or without platinum-containing chemotherapy, versus standard of care gemcitabine + platinum-containing chemotherapy, in subjects with previously untreated locally advanced or metastatic urothelial cancer."
1610,UNCHANGED,Covered Recipient Teaching Hospital,,380009.0,11212.0,Ohsu Hospital And Clinics,,,,,,,3181 SW SAM JACKSON PARK RD,,PORTLAND,OR,97239,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,350193.0,1720216401.0,RONAN,THOMAS,SWORDS,,3303 S BOND AVE,,PORTLAND,OR,97239,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,FL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Incyte Corporation,100000000263,Incyte Corporation,DE,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.65,08/09/2021,Cash or cash equivalent,,,,,,,No,No,"A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis",No,831061251,2021,01/20/2023,,,"Payments or transfers of value related to research are provided to a studys respective site and associated, per CMS requirements, with a Principal Investigator. The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and study drug."
5434,UNCHANGED,Covered Recipient Teaching Hospital,,460009.0,11165.0,U OF U HOSPITALS & CLINICS,,,,,,,50 N Medical Dr,,Salt Lake City,UT,84132,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,821548.0,1104093392.0,JAMIE,,RHOADS,,6095 S FASHION BLVD,,MURRAY,UT,84107-7397,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Dermatology,,,,,,HI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Regeneron Pharmaceuticals, Inc.",100000000069,"Regeneron Pharmaceuticals, Inc.",NY,United States,Yes,Covered,Biological,INFLAMMATION AND  IMMUNOLOGY,DUPIXENT,0024-5914-01,,,,,,,,,,,,,,,,,,,,,,,,,,3792.38,11/11/2021,Cash or cash equivalent,,,,,,,No,No,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH BULLOUS PEMPHIGOID",No,793090433,2021,01/20/2023,NCT04206553,,
3031,UNCHANGED,Covered Recipient Teaching Hospital,,13301.0,10922.0,Usa Childrens And Womens Hospital,,,,,,,1700 CENTER ST,,MOBILE,AL,36604,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1385699.0,1942512637.0,SACHIN,G.,PAI,,1660 SPRING HILL AVE,,MOBILE,AL,36604,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,,,,,,AL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Incyte Corporation,100000000263,Incyte Corporation,DE,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,136.4,10/30/2021,Cash or cash equivalent,,,,,,,No,No,"Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors",No,831130213,2021,01/20/2023,,,"Payments or transfers of value related to research are provided to a studys respective site and associated, per CMS requirements, with a Principal Investigator. The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and study drug."
973,UNCHANGED,Covered Recipient Teaching Hospital,,100038.0,10846.0,MEMORIAL REGIONAL HOSPITAL,,,,,,,3501 Johnson St,,Hollywood,FL,33021,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,42246.0,1922030071.0,LUIS,E,RAEZ,,801 N FLAMINGO RD STE 11,,PEMBROKE PINES,FL,33028,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,FL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Pfizer Inc.,100000000286,PFIZER INC.,NY,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8500.0,04/02/2021,Cash or cash equivalent,,,,,,,No,No,A PHASE 1 STUDY TO EVALUATE THE SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF06939999 PRMT5 INHIBITOR IN PARTICIPANTS WITH ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA ESOPHAGEAL CANCER ENDOMETRIAL CANCER CERVICAL CANCER AND BLADDER CANCER,No,832695755,2021,01/20/2023,,,
8502,UNCHANGED,Covered Recipient Teaching Hospital,,440039.0,10425.0,VANDERBILT UNIVERSITY MEDICAL CENTER,,,,,,,1211 Medical Center Drive,,Nashville,TN,37232,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,5076219.0,1134485410.0,WADE,THOMAS,IAMS,,3601 THE VANDERBILT CLINIC,,NASHVILLE,TN,37232,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,IL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000337,"Takeda Pharmaceuticals U.S.A., Inc.",IL,United States,Yes,Non-Covered,Drug,,EXKIVITY,63020-040-90,,,,,,,,,,,,,,,,,,,,,,,,,,1613.0,01/26/2021,Cash or cash equivalent,,,,,,,No,No,"A PHASE 1/2 STUDY OF THE SAFETY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF THE ORAL EGFR/HER2 INHIBITOR TAK-788 (AP32788) IN NON-SMALL CELL LUNG CANCER",No,816676037,2021,01/20/2023,NCT02716116,,
5409,UNCHANGED,Covered Recipient Teaching Hospital,,460009.0,11165.0,U OF U HOSPITALS & CLINICS,,,,,,,50 N Medical Dr,,Salt Lake City,UT,84132,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,821548.0,1104093392.0,JAMIE,,RHOADS,,4488 HANALEI PLANTATION RD,,PRINCEVILLE,HI,96722,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Dermatology,,,,,,UT,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Pfizer Inc.,100000000286,PFIZER INC.,NY,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1617.77,04/08/2021,Cash or cash equivalent,,,,,,,No,No,A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF06650833 PF06700841 AND PF06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA,No,832547919,2021,01/20/2023,,,
7216,UNCHANGED,Covered Recipient Teaching Hospital,,160058.0,10604.0,UNIVERSITY OF IOWA HOSP & CLINICS,,,,,,,200 Hawkins Dr,,Iowa City,IA,52242,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1014744.0,1871756163.0,YOUSEF,N,ZAKHARIA,,200 HAWKINS DR,DEP OF INTERNAL MEDICINE,IOWA CITY,IA,52242-1009,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,IA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Kyowa Kirin, Inc.",100000010604,"Kyowa Kirin, Inc.",NJ,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,107.1,04/01/2021,Cash or cash equivalent,,,,,,,No,No,Kyowa Kirin 2455-002,No,853000343,2021,01/20/2023,,,
6153,UNCHANGED,Covered Recipient Physician,,,,,702573.0,1902035066.0,HARLAN,B.,HARVEY,,115 Flash Rd,,Nahant,MA,01908,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine,,,,,,MA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bristol Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,United States,Yes,Covered,Biological,Oncology,OPDIVO,0003-3774-12,,,,,,,,,,,,,,,,,,,,,,,,,,17865.0,06/08/2021,Cash or cash equivalent,,,,,,,No,No,Phase III Adjuvant Bladder nivo mono,No,819889469,2021,01/20/2023,,,
2238,UNCHANGED,Covered Recipient Teaching Hospital,,220162.0,9984.0,DANA-FARBER CANCER INSTITUTE,,,,,,,450 BROOKLINE AVE,,BOSTON,MA,02215,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,931223.0,1942297189.0,RACHEL,A,FREEDMAN,,450 BROOKLINE AVE,,BOSTON,MA,02215-5418,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine,,,,,,MA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"PUMA BIOTECHNOLOGY, INC.",100000191750,"PUMA BIOTECHNOLOGY, INC.",CA,United States,Yes,Covered,Drug,ONCOLOGY,NERLYNX,70437-240-18,,,,,,,,,,,,,,,,,,,,,,,,,,65000.0,10/28/2021,Cash or cash equivalent,,,,,,,No,No,AN OPEN-LABEL STUDY TO CHARACTERIZE THE INCIDENCE AND SEVERITY OF DIARRHEA IN PATIENTS WITH EARLY-STAGE HER2+ BREAST CANCER TREATED WITH NERATINIB AND INTENSIVE LOPERAMIDE PROPHYLAXIS,No,834097151,2021,01/20/2023,,,
9043,UNCHANGED,Covered Recipient Teaching Hospital,,500027.0,11177.0,SWEDISH MEDICAL CENTER,,,,,,,747 Broadway,,Seattle,WA,98122,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,513179.0,1285743922.0,RAYA,,MAWAD,,1221 MADISON ST,2ND FLOOR,SEATTLE,WA,98104-3588,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology,,,,,,WA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ABBVIE INC.,100000000204,ABBVIE INC.,IL,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,615.0,12/20/2021,Cash or cash equivalent,,,,,,,No,No,A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Subjects with Relapsed/Refractory Acute Myeloid Leukemia (AML),No,792398899,2021,01/20/2023,NCT03360006,,M16-415
8238,UNCHANGED,Covered Recipient Teaching Hospital,,390111.0,10224.0,Hospital Of The Univ Of Penna,,,,,,,3701 Market St,,Phila,PA,19104,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,18606.0,1417987652.0,JASON,,FRITZ,,3400 CIVIC CENTER BLVD FL 1,,PHILADELPHIA,PA,19104-5161,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Critical Care Medicine,,,,,,PA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1181.0,05/14/2021,Cash or cash equivalent,,,,,,,No,No,Uptravi Selexipag the users drug registry,No,787584235,2021,01/20/2023,,,
3701,UNCHANGED,Covered Recipient Teaching Hospital,,363300.0,10334.0,CHILDRENS HOSPITAL MEDICAL CENTER,,,,,,,3333 Burnet Ave,,Cincinnati,OH,45229,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1232941.0,1558378943.0,ROBERT,WILSON,FRENCK,JR.,3333 BURNET AVE,,CINCINNATI,OH,45229,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pediatrics,,,,,,OH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Pfizer Inc.,100000000286,PFIZER INC.,NY,United States,Yes,Covered,Biological,VACCINES,TRUMENBA,0005-0100-05,,,,,,,,,,,,,,,,,,,,,,,,,,830.25,05/21/2021,Cash or cash equivalent,,,,,,,No,No,A PHASE 2B RANDOMIZED OBSERVERBLINDED TRIAL TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY ADMINISTERED ON 2 DIFFERENT DOSING SCHEDULES IN HEALTHY PARTICIPANTS 11 TO 15 YEARS OF AGE,No,832678727,2021,01/20/2023,,,
6895,UNCHANGED,Covered Recipient Teaching Hospital,,470003.0,9973.0,University Of Vermont Medical Center,,,,,,,111 COLCHESTER AVE,,BURLINGTON,VT,05401,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,956284.0,1831113703.0,FRANK,P.,ITTLEMAN,,111 Colchester Ave,# 142,BURLINGTON,VT,05401,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Thoracic Surgery (Cardiothoracic Vascular Surgery),,,,,,NY,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,United States,Yes,Covered,Device,Transcatheter Valve Systems,CoreValve Evolut,,00643169565623,,,,,,,,,,,,,,,,,,,,,,,,,4838.5,10/20/2021,Cash or cash equivalent,,,,,,,No,No,TAVR Low Risk,No,801014815,2021,01/20/2023,,,
1110,UNCHANGED,Covered Recipient Teaching Hospital,,390111.0,10224.0,HOSPITAL OF THE UNIV OF PENNA,,,,,,,3701 Market St,,Phila,PA,19104,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,24935.0,1558534172.0,SAMEER,J,KHANDHAR,,51 N 39TH ST,PHI 2C,PHILADELPHIA,PA,19104-2640,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology,,,,,,NJ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Inari Medical, Inc.",100000121364,"Inari Medical, Inc.",CA,United States,Yes,Covered,Device,VTE,"FLOWTRIEVER CATHETER, S",,00850291007000,,,,,,,,,,,,,,,,,,,,,,,,,135.0,06/30/2021,Cash or cash equivalent,,,,,,,No,No,FLOWTRIEVER ALL-COMER REGISTRY FOR PATIENT SAFETY AND HEMODYNAMICS (FLASH),No,850618563,2021,01/20/2023,NCT03761173,,
4839,UNCHANGED,Covered Recipient Teaching Hospital,,410012.0,10006.0,The Miriam Hospital,,,,,,,164 SUMMIT AVENUE,,PROVIDENCE,RI,02904,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,156468.0,1467447763.0,PETER,,SOUKAS,,208 COLLYER ST,,PROVIDENCE,RI,02904,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology,,,,,,MA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,United States,Yes,Non-Covered,Device,Clinical Trial Product,DESBTK,,,,,,,,,,,,,,,,,,,,,,,,,,,2229.0,12/06/2021,Cash or cash equivalent,,,,,,,No,No,ELEGANCE,No,800047395,2021,01/20/2023,,,
9773,UNCHANGED,Covered Recipient Physician,,,,,334925.0,1376560136.0,AJAI,,CHARI,,"1 GUSTAVE L. LEVY PLACE, BOX 1185",MOUNT SINAI MEDICAL CENTER,NEW YORK,NY,10029,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,NY,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Amgen Inc.,100000000203,Amgen Inc.,CA,United States,Yes,Covered,Drug,Oncology,Kyprolis,76075-101-01,,,,,,,,,,,,,,,,,,,,,,,,,,7626.33,09/29/2021,In-kind items and services,,,,,,,No,No,"A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly",No,830977985,2021,01/20/2023,,,
2935,UNCHANGED,Covered Recipient Teaching Hospital,,490063.0,10733.0,Inova Fairfax Hospital,,,,,,,3300 Gallows Rd,,Falls Church,VA,22042,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,303786.0,1689895153.0,HENRY,AN,TRAN,,3580 JOSEPH SIEWICK DR,STE 401,FAIRFAX,VA,22033,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease,,,,,,NY,VA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,Denmark,Yes,Non-Covered,Drug,Diabetes,,,,,,,,,,,,,,,,,,,,,,,,,,,,180.0,04/12/2021,In-kind items and services,,,,,,,No,No,EX9536-4388,No,811822611,2021,01/20/2023,,,
710,UNCHANGED,Covered Recipient Teaching Hospital,,500008.0,11198.0,University Of Washington Med Ctr,,,,,,,1959 Ne Pacific St,,Seattle,WA,98195,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1078037.0,1114002938.0,SCOTT,,TYKODI,,UNIVERSITY OF WASHINGTON MEDICAL CTR,1959 NE PACIFIC ST,SEATTLE,WA,98195,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,,,,,,WA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,United States,Yes,Covered,Drug,Oncology,CABOMETYX,42388-023-26,,,,,,,,,,,,,,,,,,,,,,,,,,2600.0,07/30/2021,Cash or cash equivalent,,,,,,,No,No,"A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris",No,838853947,2021,01/20/2023,,,
8734,UNCHANGED,Covered Recipient Teaching Hospital,,40014.0,10968.0,White County Medical Center,,,,,,,504 W Main St # A,,Bradford,AR,72020,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,355617.0,1831154343.0,DAVID,M,JOHNSON,,2900 HAWKINS DR,,SEARCY,AR,72143,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine,,,,,,AR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,Denmark,Yes,Covered,Drug,Diabetes,RYBELSUS,0169-4303-13,,,,,,,,,,,,,,,,,,,,,,,,,,9.95,02/03/2021,In-kind items and services,,,,,,,No,No,EX9924-4473,No,811837845,2021,01/20/2023,,,
8260,UNCHANGED,Covered Recipient Teaching Hospital,,100271.0,10837.0,Moffitt Cancer Center,,,,,,,12902 Magnolia Dr,,Tampa,FL,33612,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,709029.0,1124227780.0,JINGSONG,,ZHANG,,12902 USF MAGNOLIA DR,H LEE MOFFITT CANCER CENTER,TAMPA,FL,33612,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,,,,,,FL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,United States,Yes,Covered,Drug,Oncology,CABOMETYX,42388-023-26,,,,,,,,,,,,,,,,,,,,,,,,,,4311.2,01/26/2021,Cash or cash equivalent,,,,,,,No,No,Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,No,838849995,2021,01/20/2023,NCT03170960,,
214,UNCHANGED,Covered Recipient Teaching Hospital,,420102.0,11093.0,Ph Patewood Hospital,,,,,,,175 Patewood Drive,,Greenville,SC,29615,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,219729.0,1851396295.0,WILLIAM,JEFFERY,EDENFIELD,,900 W FARIS RD,,GREENVILLE,SC,29605,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,SC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"EMD Serono, Inc.",100000000127,"EMD Serono, Inc.",MA,United States,Yes,Covered,Drug,Oncology,Bavencio,44087-3535-1,,,,,,,,,,,,,,,,,,,,,,,,,,2414.0,01/25/2021,Cash or cash equivalent,,,,,,,No,No,MS201964-0001,No,842904477,2021,01/20/2023,,,
735,UNCHANGED,Covered Recipient Teaching Hospital,,13301.0,10922.0,Usa Childrens And Womens Hospital,,,,,,,1700 CENTER ST,,MOBILE,AL,36604,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1385699.0,1942512637.0,SACHIN,G.,PAI,,1660 SPRING HILL AVE,,MOBILE,AL,36604,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,,,,,,AL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Incyte Corporation,100000000263,Incyte Corporation,DE,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,136.4,10/30/2021,Cash or cash equivalent,,,,,,,No,No,"Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors",No,831130231,2021,01/20/2023,,,"Payments or transfers of value related to research are provided to a studys respective site and associated, per CMS requirements, with a Principal Investigator. The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and study drug."
2867,UNCHANGED,Covered Recipient Teaching Hospital,,390111.0,10224.0,Hospital Of The Univ Of Penna,,,,,,,3701 MARKET ST,,PHILA,PA,19104,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,971548.0,1356518724.0,AMY,,CLARK,,3400 Civic Center Blvd,,PHILADELPHIA,PA,19104,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine,,,,,,PA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Seagen Inc.,100000000279,Seagen Inc.,WA,United States,Yes,Covered,Drug,Oncology,TUKYSA,51144-001-60,,,,,,,,,,,,,,,,,,,,,,,,,,1600.0,04/28/2021,Cash or cash equivalent,,,,,,,No,No,"Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib",No,792657063,2021,01/20/2023,NCT02614794,https://clinicaltrials.gov/ct2/show/NCT02614794,
4421,UNCHANGED,Covered Recipient Teaching Hospital,,220071.0,9988.0,Massachusetts General Hospital,,,,,,,55 FRUIT ST,BULFINCH 360,BOSTON,MA,02114,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,62113.0,1366423832.0,THEOFANIE,,MELA,,55 FRUIT ST,GRB 109 CARDIAC EP LAB,BOSTON,MA,02114,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease,,,,,,MA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,United States,Yes,Covered,Device,Cardiology/Vascular Diseases,Rivacor,,04035479156794,Covered,Device,Cardiology/Vascular Diseases,Solia,,04035479118266,Covered,Device,Cardiology/Vascular Diseases,Acticor,,04035479156701,Covered,Device,Cardiology/Vascular Diseases,Sentus,,4035479148942.0,Covered,Device,Cardiology/Vascular Diseases,Plexa,,4035479140014.0,325.76,12/14/2021,Cash or cash equivalent,,,,,,,No,No,BIO-LIBRA,No,843819171,2021,01/20/2023,,,
2893,UNCHANGED,Covered Recipient Teaching Hospital,,390111.0,10224.0,Hospital Of The Univ Of Penna,,,,,,,3400 Spruce Street,,Philadelphia,PA,19104,United States,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"UCB, Inc.",100000010773,UCB SA,,Belgium,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,21187.0,06/01/2021,Cash or cash equivalent,,,,,,,No,No,AN OPEN-LABEL EXTENSION STUDY TO EVALUATE ROZANOLIXIZUMAB IN STUDY PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS,No,844226617,2021,01/20/2023,NCT04650854,,
6114,ADD,Covered Recipient Teaching Hospital,,390111.0,10224.0,Hospital Of The Univ Of Penna,,,,,,,3701 MARKET ST,,PHILADELPHIA,PA,19104,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,755610.0,1760579601.0,DREW,,WEISSMAN,,3900 WOODLAND AVE,,PHILADELPHIA,PA,19104,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Allergy & Immunology,,,,,,PA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BioNTech SE,100000971889,BioNTech SE,,Germany,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1700.0,07/30/2021,Cash or cash equivalent,,,,,,,Yes,No,,No,851138609,2021,01/20/2023,,,
6750,UNCHANGED,Covered Recipient Teaching Hospital,,220071.0,9988.0,MASSACHUSETTS GENERAL HOSPITAL,,,,,,,55 Fruit St,Bulfinch 360,Boston,MA,02114,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,196739.0,1326174038.0,KATHLEEN,E,COREY,,MASSACHUSETTS GENERAL HOSPITAL,55 FRUIT STREET,BOSTON,MA,02114,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology,,,,,,MA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Intercept Pharmaceuticals, Inc.",100000151645,"INTERCEPT PHARMACEUTICALS, INC.",NY,United States,Yes,Covered,Drug,HEPATOLOGY  GASTROENTEROLOGY,OCALIVA,,,,,,,,,,,,,,,,,,,,,,,,,,,1597.37,10/20/2021,Cash or cash equivalent,,,,,,,No,No,Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE),No,836192565,2021,01/20/2023,NCT02548351,,
2334,UNCHANGED,Covered Recipient Teaching Hospital,,110010.0,10785.0,Emory University Hospital,,,,,,,1821 Clifton Rd Ne,,Atlanta,GA,30329,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,340223.0,1487819132.0,YAZAN,,DUWAYRI,,DIVISION OF VASCULAR SURGERY EMORY CLINIC BLDG A,1365 CLIFTON ROAD NE. 3RD FLOOR,ATLANTA,GA,30322,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery,,,,,,GA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cook Medical LLC,100000005386,Cook Research Incorporated,IN,United States,Yes,Covered,Device,Aortic Intervention,Cook Medical Advanced Tech,,,,,,,,,,,,,,,,,,,,,,,,,,,302.0,02/17/2021,Cash or cash equivalent,,,,,,,No,No,Zenith p-Branch Endovascular Graft - Pivotal Study,No,842541509,2021,01/20/2023,,,
2100,UNCHANGED,Covered Recipient Teaching Hospital,,220071.0,9988.0,Massachusetts General Hospital,,,,,,,55 Fruit St,Bulfinch 360,Boston,MA,02114,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,967837.0,1225322258.0,MICHAEL,LAWRENCE,DOUGAN,,55 FRUIT ST,,BOSTON,MA,02114,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology,,,,,,MA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Pfizer Inc.,100000000286,PFIZER INC.,NY,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,18097.5,10/21/2021,Cash or cash equivalent,,,,,,,No,No,A PHASE 1B 2PART DOUBLEBLIND PLACEBOCONTROLLED SPONSOROPEN STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING 24HOUR PART 1 AND MULTIPLE ASCENDING 120HOUR PART 2 INTRAVENOUS INFUSIONS OF PF07304814 IN HOSPITALIZED PARTICIPANTS WITH COVID19,No,832514337,2021,01/20/2023,,,
7114,UNCHANGED,Covered Recipient Teaching Hospital,,220110.0,9985.0,Brigham And Womens Hospital,,,,,,,75 Francis St,,Boston,MA,02115,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,116914.0,1588748883.0,VANITA,R,ARODA,,221 LONGWOOD AVE,# RFB-2,BOSTON,MA,02115,United States,,,Medical Doctor,,,,,,"Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism",,,,,,CA,MA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,Denmark,Yes,Non-Covered,Drug,Diabetes,,,,,,,,,,,,,,,,,,,,,,,,,,,,26.5,06/14/2021,In-kind items and services,,,,,,,No,No,EX9536-4388,No,810790125,2021,01/20/2023,,,
5502,UNCHANGED,Covered Recipient Teaching Hospital,,50696.0,11289.0,KECK HOSPITAL OF USC,,,,,,,1500 San Pablo Street,,Los Angeles,CA,90033,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,92292.0,1043249584.0,DAVID,I,QUINN,,1441 EASTLAKE AVE,,LOS ANGELES,CA,90089,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,,,,,,CA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Pfizer Inc.,100000000286,PFIZER INC.,NY,United States,Yes,Covered,Drug,ONCOLOGY,BAVENCIO,44087-3535-1,,Covered,Drug,ONCOLOGY,INLYTA,0069-0145-01,,,,,,,,,,,,,,,,,,,,27714.0,12/13/2021,In-kind items and services,,,,,,,No,No,A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA,No,832515899,2021,01/20/2023,,,Study Drug
1208,UNCHANGED,Covered Recipient Teaching Hospital,,440039.0,10425.0,Vanderbilt University Medical Center,,,,,,,1211 MEDICAL CENTER DRIVE,,NASHVILLE,TN,37232,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,857066.0,1356499438.0,ASHLEY,H.,SHOEMAKER,,1500 21STAVE SOUTH,,NASHVILLE,TN,37212,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pediatrics|Pediatric Endocrinology,,,,,,TN,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Rhythm Pharmaceuticals, Inc.",100000966832,"Rhythm Pharmaceuticals, Inc.",MA,United States,Yes,Covered,Drug,Genetic Disease,Imcivree,72829-010-01,,,,,,,,,,,,,,,,,,,,,,,,,,27875.0,11/19/2021,Cash or cash equivalent,,,,,,,No,No,RM-493-030,No,843299759,2021,01/20/2023,,,
7078,UNCHANGED,Covered Recipient Teaching Hospital,,360180.0,10373.0,Cleveland Clinic Hospital,,,,,,,9500 Euclid Ave,,Cleveland,OH,44195,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,416726.0,1871581611.0,CHRISTY,,SAMARAS,,9500 EUCLID AVE,DESK R35,CLEVELAND,OH,44195-0001,United States,,,Doctor of Osteopathy,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,OH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,200.0,12/02/2021,Cash or cash equivalent,,,,,,,No,No,A Phase 3 Randomized Multi Center Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High risk Smoldering Multiple Myeloma,No,787580023,2021,01/20/2023,,,
9354,UNCHANGED,Covered Recipient Teaching Hospital,,180103.0,10847.0,Baptist Health Lexington,,,,,,,1740 NICHOLASVILLE RD,,LEXINGTON,KY,40503,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,32625.0,1730127994.0,CRAIG,JENNINGS,MCCOTTER,,1720 NICHOLASVILLE RD STE 601,,LEXINGTON,KY,40503,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Clinical Cardiac Electrophysiology,,,,,,KY,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,United States,Yes,Covered,Device,Cardiology/Vascular Diseases,Plexa,,04035479140014,Covered,Device,Cardiology/Vascular Diseases,Solia,,04035479118266,Covered,Device,Cardiology/Vascular Diseases,Rivacor,,04035479156794,Covered,Device,Cardiology/Vascular Diseases,Sentus,,4035479148942.0,Covered,Device,Cardiology/Vascular Diseases,Acticor,,4035479156701.0,158.0,04/13/2021,Cash or cash equivalent,,,,,,,No,No,BIO-LIBRA,No,843839331,2021,01/20/2023,,,
7926,UNCHANGED,Covered Recipient Physician,,,,,177687.0,1912059221.0,STEWART,J.,TEPPER,,1 MEDICAL CENTER DR,DHMC/NEUROLOGY,LEBANON,NH,03756,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology,,,,,,NH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Amgen Inc.,100000000203,Amgen Inc.,CA,United States,Yes,Covered,Biological,Neuroscience,Aimovig,55513-841-01,,,,,,,,,,,,,,,,,,,,,,,,,,3875.65,10/05/2021,In-kind items and services,,,,,,,No,No,Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing data,No,830986249,2021,01/20/2023,,,
8308,UNCHANGED,Covered Recipient Teaching Hospital,,360059.0,10399.0,Metrohealth Medical Center,,,,,,,2500 Metrohealth Drive,,Cleveland,OH,44109,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1244883.0,1972639946.0,CORRILYNN,OLESKY,HILEMAN,,2500 METROHEALTH DR,,CLEVELAND,OH,44109,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease,,,,,,OH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Gilead Sciences, Inc.",100000000108,"Gilead Sciences, Inc.",CA,United States,Yes,Covered,Drug,HIV,Biktarvy,61958-2501-1,,,,,,,,,,,,,,,,,,,,,,,,,,500.0,07/14/2021,Cash or cash equivalent,,,,,,,No,No,"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",No,803514323,2021,01/20/2023,,,;GS-US-380-1489;G2758873;IPP;346004382;10443057
9968,UNCHANGED,Covered Recipient Teaching Hospital,,430016.0,10639.0,AVERA MCKENNAN,,,,,,,6709 S Minnesota Ave Ste 102,,Sioux Falls,SD,57108,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,135009.0,1972579118.0,JAWAD,,NAZIR,,6709 S MINNESOTA AVE STE 102,,SIOUX FALLS,SD,57108-2593,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease,,,,,,SD,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Regeneron Pharmaceuticals, Inc.",100000000069,"Regeneron Pharmaceuticals, Inc.",NY,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2276.1,05/27/2021,Cash or cash equivalent,,,,,,,No,No,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2",No,793085565,2021,01/20/2023,NCT04452318,,
2902,UNCHANGED,Covered Recipient Teaching Hospital,,500027.0,11177.0,Swedish Medical Center,,,,,,,747 Broadway,,Seattle,WA,98122,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,289631.0,1376633222.0,JOHN,MICHAEL,PAGEL,,1221 MADISON ST STE 1020,,SEATTLE,WA,98104,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,WA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,AstraZeneca Pharmaceuticals LP,100000010370,AstraZeneca UK Limited,,Great Britain (Uk),Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,345.62,12/31/2021,In-kind items and services,,,,,,,No,No,A Platform Protocol for the Treatment of Relapsed /Refractory Aggressive Non-Hodgkin's Lymphoma,No,826493559,2021,01/20/2023,,,
9677,UNCHANGED,Covered Recipient Teaching Hospital,,500027.0,11177.0,Swedish Medical Center,,,,,,,747 Broadway,,Seattle,WA,98122,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,60322.0,1336218171.0,PHILIP,J,MEASE,,1101 MADISON ST STE 1000,,SEATTLE,WA,98104-3556,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology,,,,,,WA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"UCB, Inc.",100000010773,UCB SA,,Belgium,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,500.0,10/18/2021,Cash or cash equivalent,,,,,,,No,No,"A MULTICENTER, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS",No,844227243,2021,01/20/2023,NCT03896581,,
3996,UNCHANGED,Covered Recipient Teaching Hospital,,110010.0,10785.0,Emory University Hospital,,,,,,,1821 Clifton Rd Ne,,Atlanta,GA,30329,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,203179.0,1477545499.0,Micah,R,Fisher,,1365A Clifton Rd Ne,4Th Floor,Atlanta,GA,30322-1013,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease,,,,,,GA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,United Therapeutics Corporation,100000010739,United Therapeutics Corporation,NC,United States,Yes,Covered,Drug,PAH,TYVASO,66302-206-01,,,,,,,,,,,,,,,,,,,,,,,,,,1560.0,03/24/2021,Cash or cash equivalent,,,,,,,No,No,"Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso",No,838859337,2021,01/20/2023,,,
859,UNCHANGED,Covered Recipient Teaching Hospital,,220116.0,10001.0,Tufts Medical Center,,,,,,,750 WASHINGTON ST,BOX 018,BOSTON,MA,02111,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1010770.0,1730353665.0,DAVID,,ROSMARIN,,800 WASHINGTON ST,DEPT OF DERMATOLOGY,BOSTON,MA,02111,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Dermatology,,,,,,MA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Incyte Corporation,100000000263,Incyte Corporation,DE,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1023.0,04/23/2021,Cash or cash equivalent,,,,,,,No,No,"A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo",No,831107501,2021,01/20/2023,,,Transfer of value for editorial and or medical writing services. These services were funded by Incyte Corporation and paid to a third-party vendor to assist with the development of a publication at the direction of the authors. No payments were made directly to the authors for these editorial and or medical writing services.
9249,UNCHANGED,Covered Recipient Teaching Hospital,,310001.0,10178.0,Hackensack University Medical Center,,,,,,,30 PROSPECT AVE,,HACKENSACK,NJ,07601,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,206058.0,1558562793.0,MARTIN,E.,GUTIERREZ,,92 2ND ST,,HACKENSACK,NJ,07601,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,FL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Incyte Corporation,100000000263,Incyte Corporation,DE,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,105.9,03/08/2021,Cash or cash equivalent,,,,,,,No,No,"A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies",No,831057503,2021,01/20/2023,,,"Payments or transfers of value related to research are provided to a studys respective site and associated, per CMS requirements, with a Principal Investigator. The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and study drug."
985,UNCHANGED,Covered Recipient Teaching Hospital,,50348.0,11307.0,UCI MEDICAL CENTER,,,,,,,101 The City Dr S,,Orange,CA,92868,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,120319.0,1669577276.0,SUSAN,M,O BRIEN,,101 THE CITY DRIVE SOUTH,BLDG 23 RM 403,ORANGE,CA,92868,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,,,,,,CA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Pharmacyclics LLC, an AbbVie Company",100000136439,"Pharmacyclics LLC, An AbbVie Company",CA,United States,Yes,Covered,Drug,ONCOLOGY,IMBRUVICA,57962-420-28,,,,,,,,,,,,,,,,,,,,,,,,,,1000.0,12/16/2021,Cash or cash equivalent,,,,,,,No,No,Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma,No,786500631,2021,01/20/2023,NCT02910583,,PCYC-1142-CA
9777,UNCHANGED,Covered Recipient Teaching Hospital,,380009.0,11212.0,OHSU HOSPITAL AND CLINICS,,,,,,,3181 SW Sam Jackson Park Rd,,Portland,OR,97239,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,451601.0,1093892648.0,AIMEE,D,KOHN,,10000 SE MAIN ST STE 350,,PORTLAND,OR,97216,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,OR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Pfizer Inc.,100000231820,ARRAY BIOPHARMA INC,CO,United States,Yes,Covered,Drug,ONCOLOGY,BRAFTOVI,70255-025-01,,Covered,Drug,ONCOLOGY,MEKTOVI,70255-010-02,,,,,,,,,,,,,,,,,,,,1876.0,07/22/2021,Cash or cash equivalent,,,,,,,No,No,A PHASE 2 OPENLABEL RANDOMIZED MULTICENTER TRIAL OF ENCORAFENIB  BINIMETINIB EVALUATING A STANDARDDOSE AND A HIGHDOSE REGIMEN IN PATIENTS WITH BRAFV600MUTANT MELANOMA BRAIN METASTASIS,No,832846079,2021,01/20/2023,,,
862,UNCHANGED,Covered Recipient Teaching Hospital,,230053.0,10500.0,HENRY FORD HOSPITAL,,,,,,,2799 W GRAND BLVD,,DETROIT,MI,48202,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,54279.0,1184792632.0,DAVID,E,LANFEAR,,2799 W GRAND BLVD K1411,,DETROIT,MI,48202,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease,,,,,,MI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,23717.73,10/11/2021,In-kind items and services,,,,,,,No,No,"A SINGLE-DOSE STUDY EVALUATING DIFFERENT DOSE LEVELS AND SUBCUTANEOUS INFUSION DURATIONS ON SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3461767 IN PARTICIPANTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION",No,819448329,2021,01/20/2023,NCT04840914,https://clinicaltrials.gov/ct2/show/NCT04840914,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor"
4565,UNCHANGED,Covered Recipient Physician,,,,,91949.0,1013927649.0,JAMES,LAWRENCE,FERRARA,,1470 Madison Ave Fl 6,,New York,NY,10029,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pediatrics|Pediatric Hematology-Oncology,,,,,,MI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",MA,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,550.0,08/02/2021,Cash or cash equivalent,,,,,,,No,No,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants Who Have Thrombotic Microangiopathy (TMA) After Hematopoietic Stem Cell Transplant (HSCT)",No,781375479,2021,01/20/2023,NCT04543591,,
4116,UNCHANGED,Covered Recipient Teaching Hospital,,160058.0,10604.0,University Of Iowa Hosp & Clinics,,,,,,,200 HAWKINS DR,,IOWA CITY,IA,52242,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,4895086.0,1215439708.0,ERNESTO,ANIBAL,RUIZ DUQUE,,200 Hawkins Dr,,Iowa City,IA,52242-1009,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine,,,,,,IA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Alnylam Pharmaceuticals Inc.,100000481817,Alnylam Pharmaceuticals Inc.,MA,United States,Yes,Covered,Drug,Genetic Disease,ONPATTRO,71336-1000-1,,,,,,,,,,,,,,,,,,,,,,,,,,724.5,08/12/2021,Cash or cash equivalent,,,,,,,No,No,"APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)",No,828416193,2021,01/20/2023,NCT03997383,,
1316,UNCHANGED,Covered Recipient Teaching Hospital,,363300.0,10334.0,CHILDRENS HOSPITAL MEDICAL CENTER,,,,,,,3333 Burnet Ave,,Cincinnati,OH,45229,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1232941.0,1558378943.0,ROBERT,WILSON,FRENCK,JR.,3333 BURNET AVE,,CINCINNATI,OH,45229,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pediatrics,,,,,,OH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Pfizer Inc.,100000000286,PFIZER INC.,NY,United States,Yes,Covered,Biological,VACCINES,COMIRNATY,0069-1000-03,,,,,,,,,,,,,,,,,,,,,,,,,,69467.22,07/03/2021,Cash or cash equivalent,,,,,,,No,No,A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS,No,832682089,2021,01/20/2023,,,
4145,UNCHANGED,Covered Recipient Teaching Hospital,,63301.0,11125.0,Childrens Hospital Colorado,,,,,,,13123 East 16th Avenue,,Aurora,CO,80045,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,411718.0,1700961430.0,ROBIN,R,DETERDING,,13123 E 16TH AVE,,AURORA,CO,80045-7106,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pediatrics|Pediatric Pulmonology,,,,,,CO,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Boehringer Ingelheim USA, Inc.",100000005541,Boehringer Ingelheim International GmbH,,Germany,Yes,Covered,Drug,RESPIRATORY,OFEV,0597-0143-60,,,,,,,,,,,,,,,,,,,,,,,,,,138.33,01/15/2021,In-kind items and services,,,,,,,No,No,Pediatric ILD program,No,828345063,2021,01/20/2023,,,
4818,UNCHANGED,Covered Recipient Teaching Hospital,,220116.0,10001.0,TUFTS MEDICAL CENTER,,,,,,,750 WASHINGTON ST,BOX 018,BOSTON,MA,02111,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1010770.0,1730353665.0,DAVID,,ROSMARIN,,260 TREMONT ST FL 13 TUFTS MED,,BOSTON,MA,02116,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Dermatology,,,,,,MA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1189.52,03/08/2021,In-kind items and services,,,,,,,No,No,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA",No,819449619,2021,01/20/2023,,,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor"
5610,UNCHANGED,Covered Recipient Physician,,,,,463209.0,1508872821.0,JEFFREY,P.,CALLEN,,3810 Springhurst Blvd Ste 200,,Louisville,KY,40241,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Dermatology,,,,,,KY,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sanofi and Genzyme US Companies,100000771811,PRINCIPIA BIOPHARMA INC.,CA,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3250.0,01/12/2021,Cash or cash equivalent,,,,,,,No,No,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor PRN1008 in Moderate to Severe Pemphigus",No,838651085,2021,01/20/2023,NCT03762265,,
9118,UNCHANGED,Covered Recipient Teaching Hospital,,360112.0,10395.0,St Vincent Medical Center,,,,,,,2213 Cherry St,,Toledo,OH,43608,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,180646.0,1972555472.0,OSAMA,O,ZAIDAT,,2222 CHERRY ST,SUITE M200,TOLEDO,OH,43608,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Vascular Neurology,,,,,,OH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Penumbra, Inc.",100000010583,"Penumbra, Inc.",CA,United States,Yes,Covered,Device,Neurointervention,Smart Coil,,00814548015286,,,,,,,,,,,,,,,,,,,,,,,,,135.0,03/25/2021,Cash or cash equivalent,,,,,,,No,No,SURF,No,840444985,2021,01/20/2023,,,
3768,UNCHANGED,Covered Recipient Teaching Hospital,,450018.0,11030.0,THE UNIVERSITY OF TEXAS MEDICAL BR.,,,,,,,301 University Blvd,,Galveston,TX,77555,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,498439.0,1730463324.0,ADOLFO,E,DIAZ,,720 PLEASANTON RD,,SAN ANTONIO,TX,78214-1306,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,TX,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Epizyme, Inc.,",100000756814,"Epizyme, Inc.,",MA,United States,Yes,Covered,Drug,ONCOLOGY,TAZVERIK,72607-100-00,,,,,,,,,,,,,,,,,,,,,,,,,,280.0,12/20/2021,Cash or cash equivalent,,,,,,,No,No,"A PHASE 1B/3 DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, 3-STAGE, BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA",No,832338017,2021,01/20/2023,NCT04224493,,
5685,UNCHANGED,Covered Recipient Teaching Hospital,,220071.0,9988.0,Massachusetts General Hospital,,,,,,,55 FRUIT ST,BULFINCH 360,BOSTON,MA,02114,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1381279.0,1710120829.0,DARSHAN,,DOSHI,,55 FRUIT ST,,BOSTON,MA,02114,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology,,,,,,MA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,United States,Yes,Covered,Device,Cardiology/Vascular Diseases,Orsiro,,07640130455948,,,,,,,,,,,,,,,,,,,,,,,,,210.5,12/14/2021,Cash or cash equivalent,,,,,,,No,No,BIOFLOW-VII,No,843818569,2021,01/20/2023,,,
3865,UNCHANGED,Covered Recipient Teaching Hospital,,330270.0,10067.0,Hospital For Special Surgery,,,,,,,532-560 WEST 33RD STREET,,NEW YORK,NY,10001,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,454777.0,1215031521.0,ROBERT,F.,SPIERA,,1088 Park Ave,,New York,NY,10128,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology,,,,,,NY,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sanofi and Genzyme US Companies,100000000067,SANOFI US SERVICES INC.,NJ,United States,Yes,Covered,Drug,Oncology,REZUROCK,79802-200-30,,,,,,,,,,,,,,,,,,,,,,,,,,1975.56,12/03/2021,Cash or cash equivalent,,,,,,,No,No,A Phase 2 Randomized Placebo controlled Double blind Open label Extension Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Diffuse Cutaneous Systemic Sclerosis,No,838664335,2021,01/20/2023,,,
9007,UNCHANGED,Covered Recipient Teaching Hospital,,220171.0,9989.0,LAHEY CLINIC HOSPITAL  INC.,,,,,,,41 Mall Rd,,Burlington,MA,01805,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,131171.0,1891892691.0,FREDRIC,D,GORDON,,41 MALL RD,4 WEST,BURLINGTON,MA,01805-0001,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology,,,,,,MA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Intercept Pharmaceuticals, Inc.",100000151645,"INTERCEPT PHARMACEUTICALS, INC.",NY,United States,Yes,Covered,Drug,HEPATOLOGY  GASTROENTEROLOGY,OCALIVA,,,,,,,,,,,,,,,,,,,,,,,,,,,1350.0,03/03/2021,Cash or cash equivalent,,,,,,,No,No,Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE),No,836192369,2021,01/20/2023,NCT02548351,,
5322,UNCHANGED,Covered Recipient Physician,,,,,30973.0,1679558027.0,GIL,,YOSIPOVITCH,,1295 NW 14TH ST,,MIAMI,FL,33125-1610,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Dermatology,,,,,,FL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Regeneron Pharmaceuticals, Inc.",100000000069,"Regeneron Pharmaceuticals, Inc.",NY,United States,Yes,Covered,Biological,INFLAMMATION AND  IMMUNOLOGY,DUPIXENT,0024-5914-01,,,,,,,,,,,,,,,,,,,,,,,,,,152.0,05/01/2021,In-kind items and services,,,,,,,No,No,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB ADMINISTERED CONCOMITANTLY WITH TOPICAL CORTICOSTEROIDS IN PATIENTS, >=6 YEARS TO <12 YEARS OF AGE, WITH SEVERE ATOPIC DERMATITIS",No,793085291,2021,01/20/2023,NCT03345914,,"The transfer of value captured herein was not a distribution of cash or goods. Instead, this report captures the provision of editorial assistance provided to the authors of the underlying publication. The value of this assistance was divided among the authors of the publication."
5233,UNCHANGED,Covered Recipient Teaching Hospital,,10033.0,10929.0,UNIVERSITY OF ALABAMA HOSPITAL,,,,,,,619 19th St S,,Birmingham,AL,35249,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,2789610.0,1770764813.0,RANCE,CHADWICK,SINIARD,,619 19TH ST S,,BIRMINGHAM,AL,35249-1900,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pathology|Clinical Pathology/Laboratory Medicine,,,,,,NC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000337,"Takeda Pharmaceuticals U.S.A., Inc.",IL,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,117.0,10/05/2021,Cash or cash equivalent,,,,,,,No,No,"A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT",No,816673173,2021,01/20/2023,NCT03922308,,
9353,UNCHANGED,Covered Recipient Teaching Hospital,,310015.0,10713.0,Morristown Medical Center,,,,,,,100 Madison Ave,,Morristown,NJ,07960,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,332771.0,1336113653.0,LAWRENCE,A,SILVERMAN,,100 MADISON AVE,,MORRISTOWN,NJ,07960,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pediatrics|Pediatric Endocrinology,,,,,,NJ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,Denmark,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11.38,04/14/2021,In-kind items and services,,,,,,,No,No,NN8640-4263,No,811591229,2021,01/20/2023,,,
464,UNCHANGED,Covered Recipient Teaching Hospital,,450056.0,11002.0,ASCENSION SETON MEDICAL CENTER,,,,,,,1201 W 38TH ST,,DALLAS,TX,78705,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1252953.0,1255507943.0,POOJA,,VARSHNEY,,1301 BARBARA JORDAN BLVD,SUITE 200,AUSTIN,TX,78723-3077,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pediatrics|Pediatric Allergy/Immunology,,,,,,TX,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"AIMMUNE THERAPEUTICS, INC.",100000776814,"AIMMUNE THERAPEUTICS, INC.",CA,United States,Yes,Covered,Biological,ALLERGY,PALFORZIA,71881-113-13,,,,,,,,,,,,,,,,,,,,,,,,,,90.0,06/22/2021,Cash or cash equivalent,,,,,,,No,No,"A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY",No,849612463,2021,01/20/2023,,,
5582,UNCHANGED,Covered Recipient Teaching Hospital,,220071.0,9988.0,Massachusetts General Hospital,,,,,,,55 FRUIT ST,BULFINCH 360,BOSTON,MA,02114,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,142225.0,1124279443.0,JOHN,H.,SHIN,,55 FRUIT ST,,BOSTON,MA,02114-2621,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Neurological Surgery,,,,,,MA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NuVasive, Inc.",100000010655,"NuVasive, Inc.",CA,United States,Yes,Covered,Device,Spine/Spine Surgery,COHERE,,00887517982742,Covered,Device,Spine/Spine Surgery,Modulus,,00887517882257,,,,,,,,,,,,,,,,,,,14950.0,12/28/2021,Cash or cash equivalent,,,,,,,No,No,"A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patients with degenerative conditions of the cervical spine",No,853300721,2021,01/20/2023,,,
1131,UNCHANGED,Covered Recipient Teaching Hospital,,160083.0,10594.0,Mercy Medical Center-Des Moines,,,,,,,411 LAUREL ST,SUITE 1265,DES MOINES,IA,50314,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,15780.0,1356323380.0,DAVID,W.,MCALLISTER,,Po Box 9170,,Des Moines,IA,50306,United States,,,Doctor of Osteopathy,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease,,,,,,IA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3299.7,09/27/2021,Cash or cash equivalent,,,,,,,No,No,Early-TAVR Trial #2016-07,No,809684593,2021,01/20/2023,,,
610,UNCHANGED,Covered Recipient Teaching Hospital,,450076.0,11031.0,Ut Md Anderson Cancer Center,,,,,,,1515 HOLCOMBE BLVD,,HOUSTON,TX,77030,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,2779735.0,1821531179.0,RAPHAEL,E.,STEINER,,1515 Holcombe Blvd,,HOUSTON,TX,77030,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,,,,,,TX,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Seagen Inc.,100000000279,Seagen Inc.,WA,United States,Yes,Covered,Biological,Oncology,ADCETRIS,51144-050-01,,,,,,,,,,,,,,,,,,,,,,,,,,89270.0,05/11/2021,In-kind items and services,,,,,,,No,No,"PACIFIC: A Phase II Study to Determine the Response Kinetics, Safety and Efficacy of Brentuximab Vedotin and Nivolumab Alone and Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma",No,792673395,2021,01/20/2023,,,
8542,UNCHANGED,Covered Recipient Physician,,,,,1375990.0,1790001113.0,Jennifer,,White,,200 LOTHROP STREET,STE 3950,PITTSBURGH,PA,15213-2536,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Radiology|Diagnostic Radiology,,,,,,PA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Treace Medical Concepts, Inc.",100000136440,"Treace Medical Concepts, Inc.",FL,United States,Yes,Covered,Device,Y,Lapiplasty System,,,,,,,,,,,,,,,,,,,,,,,,,,,675.0,02/02/2021,Cash or cash equivalent,,,,,,,No,No,ALIGN3D,No,848616377,2021,01/20/2023,NCT03740350,,EARLY WEIGHT BEARING AFTER LAPIPLASTY PROCEDURE
3373,UNCHANGED,Covered Recipient Teaching Hospital,,360180.0,10373.0,Cleveland Clinic Hospital,,,,,,,9500 Euclid Ave,,Cleveland,OH,44195,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,312546.0,1902041197.0,MARCIO,L,GRIEBELER,,10685 CARNEGIE AVE,,CLEVELAND,OH,44106,United States,,,Medical Doctor,,,,,,"Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism",,,,,,MN,OH,SD,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,Denmark,Yes,Covered,Drug,Obesity,Wegovy,0169-4525-14,,,,,,,,,,,,,,,,,,,,,,,,,,5.56,09/03/2021,In-kind items and services,,,,,,,No,No,NN9536-4578,No,811903789,2021,01/20/2023,,,
4129,UNCHANGED,Covered Recipient Teaching Hospital,,230046.0,10547.0,Univ Of Mi Hospitals & Hlth Ctrs,,,,,,,1500 EAST MEDICAL CENTER DRIVE,,ANN ARBOR,MI,48109,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1149827.0,1629167549.0,CEM,,AKIN,,3621 SOUTH STATE STREET,700 KMS PLACE,ANN ARBOR,MI,48108,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Allergy & Immunology,,,,,,MA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Blueprint Medicines Corporation,100000756811,Blueprint Medicines Corporation,MA,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,15082.15,03/18/2021,Cash or cash equivalent,,,,,,,No,No,"A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy",No,848926875,2021,01/20/2023,NCT03731260,,
1176,UNCHANGED,Covered Recipient Physician,,,,,145860.0,1205849577.0,ROSARIO,,RETINO,,320 W G ST STE 101,,ONTARIO,CA,91762,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pediatrics,,,,,,CA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1002.01,01/29/2021,In-kind items and services,,,,,,,No,No,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY",No,819446529,2021,01/20/2023,NCT03432286,https://clinicaltrials.gov/ct2/show/NCT03432286,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor"
8320,UNCHANGED,Covered Recipient Teaching Hospital,,310015.0,10713.0,Morristown Medical Center,,,,,,,100 Madison Ave,,Morristown,NJ,07960,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,332771.0,1336113653.0,LAWRENCE,A,SILVERMAN,,100 MADISON AVE,,MORRISTOWN,NJ,07960,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pediatrics|Pediatric Endocrinology,,,,,,NJ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,Denmark,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,17.07,08/19/2021,In-kind items and services,,,,,,,No,No,NN8640-4245,No,811202797,2021,01/20/2023,,,
7256,UNCHANGED,Covered Recipient Teaching Hospital,,310001.0,10178.0,Hackensack University Medical Center,,,,,,,30 PROSPECT AVE,,HACKENSACK,NJ,07601,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,206058.0,1558562793.0,MARTIN,E.,GUTIERREZ,,92 2ND ST,,HACKENSACK,NJ,07601,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,FL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Incyte Corporation,100000000263,Incyte Corporation,DE,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,35.16,11/08/2021,Cash or cash equivalent,,,,,,,No,No,A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies,No,831059027,2021,01/20/2023,,,"Payments or transfers of value related to research are provided to a studys respective site and associated, per CMS requirements, with a Principal Investigator. The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and study drug."
2003,UNCHANGED,Covered Recipient Teaching Hospital,,50262.0,11328.0,RONALD REAGAN UCLA,,,,,,,757 Westwood Plz,,Los Angeles,CA,90095,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,198484.0,1386663227.0,ALLAN,,PANTUCK,,200 UCLA MEDICAL PLZ STE 140,,LOS ANGELES,CA,90095-3075,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Urology,,,,,,CA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Astellas Pharma Global Development,100000005406,Astellas Pharma Global Development,IL,United States,Yes,Covered,Drug,ONCOLOGY,XTANDI,0469-0125-99,,,,,,,,,,,,,,,,,,,,,,,,,,3780.0,10/06/2021,Cash or cash equivalent,,,,,,,No,No,A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study,No,801079081,2021,01/20/2023,,,
7380,UNCHANGED,Covered Recipient Teaching Hospital,,220071.0,9988.0,MASSACHUSETTS GENERAL HOSPITAL,,,,,,,55 Fruit St,Bulfinch 360,Boston,MA,02114,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,291398.0,1437186327.0,STEVEN,E,ARNOLD,,3535 MARKET ST,3RD FLOOR,PHILADELPHIA,PA,19104-3309,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology,,,,,,MA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ABBVIE INC.,100000000204,ABBVIE INC.,IL,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1719.3,02/08/2021,Cash or cash equivalent,,,,,,,No,No,An Extension Study of ABBV-8E12 in Early Alzheimers Disease,No,792383269,2021,01/20/2023,NCT03712787,,M15-570
2281,UNCHANGED,Covered Recipient Teaching Hospital,,50146.0,11296.0,City Of Hope National Medical Ctr,,,,,,,1500 E DUARTE RD,,DUARTE,CA,91010,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,156689.0,1467408948.0,TANYA,,SIDDIQI,,1500 Duarte Rd,,Duarte,CA,91010,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,CA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Celgene Corporation,100000000343,Celgene Corporation,NY,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,17495.75,05/26/2021,Cash or cash equivalent,,,,,,,No,No,Expanded Access Protocol (EAP) of subjects receivi,No,807111751,2021,01/20/2023,,,
1366,UNCHANGED,Covered Recipient Teaching Hospital,,500008.0,11198.0,University Of Washington Med Ctr,,,,,,,1959 NE PACIFIC ST,,SEATTLE,WA,98195,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,724176.0,1669535670.0,ANDREW,L.,COVELER,,1354 E Aloha St,,SEATTLE,WA,98102,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine,,,,,,WA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Seagen Inc.,100000000279,Seagen Inc.,WA,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,190.5,11/23/2021,Cash or cash equivalent,,,,,,,No,No,"A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies",No,792674159,2021,01/20/2023,NCT02376699,https://clinicaltrials.gov/ct2/show/NCT02376699,
5425,UNCHANGED,Covered Recipient Teaching Hospital,,450076.0,11031.0,Ut Md Anderson Cancer Center,,,,,,,1515 HOLCOMBE BLVD,,HOUSTON,TX,77030,United States,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bristol Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,United States,Yes,Covered,Biological,Oncology,OPDIVO,0003-3774-12,,,,,,,,,,,,,,,,,,,,,,,,,,78960.9,02/18/2021,Cash or cash equivalent,,,,,,,No,No,An Open-Label Preoperative Pilot Study Evaluating Nivolumab Anti-PD-1 Antibody Alone Versus Nivolumab Plus Ipilimumab Anti-CTLA-4 Antibody in Patients with Resectable and Potentially Resectable HCC,No,819881943,2021,01/20/2023,,,
7751,UNCHANGED,Covered Recipient Teaching Hospital,,63301.0,11125.0,Childrens Hospital Colorado,,,,,,,13123 East 16th Avenue,,Aurora,CO,80045,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,169043.0,1720058860.0,JAY,,ALBRIGHT,,13123 E 16TH AVE,,AURORA,CO,80045-7106,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Orthopaedic Surgery|Sports Medicine,,,,,,CO,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Smith+Nephew, Inc.",100000005456,"Smith+Nephew, Inc.",TN,United States,Yes,Covered,Device,Sports Med Resection,FLOW 50/90,,00885556647462,,,,,,,,,,,,,,,,,,,,,,,,,4480.0,03/23/2021,Cash or cash equivalent,,,,,,,No,No,"Case Report: Congenital Absence of Anterior Cruciate Ligament (note: depending on actual pediatric patient treated with FLOW50, scope of the case report may be modifie",No,826572253,2021,01/20/2023,,,
7126,UNCHANGED,Covered Recipient Teaching Hospital,,450076.0,11031.0,UT MD ANDERSON CANCER CENTER,,,,,,,1515 Holcombe Blvd,,Houston,TX,77030,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,860254.0,1467538132.0,NEETA,,SOMAIAH,,1515 HOLCOMBE BLVD,,HOUSTON,TX,77030-4000,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,,,,,,TX,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Deciphera Pharmaceuticals Inc.,100000776815,Deciphera Pharmaceuticals Inc.,MA,United States,Yes,Covered,Drug,ONCOLOGY,QINLOCK,73207-101-31,,,,,,,,,,,,,,,,,,,,,,,,,,1850.0,09/21/2021,Cash or cash equivalent,,,,,,,No,No,INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE,No,827893049,2021,01/20/2023,NCT03673501,,
3293,UNCHANGED,Covered Recipient Teaching Hospital,,140091.0,10493.0,CARLE FOUNDATION HOSPITAL,,,,,,,2300 N Vermilion St,,Danville,IL,61832,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,332895.0,1326159088.0,PAUL,M,TENDER,,963 N MCQUEEN RD,,CHANDLER,AZ,85225-8149,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Colon & Rectal Surgery,,,,,,AZ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000337,"Takeda Pharmaceuticals U.S.A., Inc.",IL,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5393.9,09/23/2021,Cash or cash equivalent,,,,,,,No,No,"A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EFFICACY AND SAFETY OF CX601, ADULT ALLOGENEIC EXPANDED ADIPOSE-DERIVED STEM CELLS (EASC) FOR THE TREATMENT OF COMPLEX PERIANAL FISTULA(S) IN PATIENTS WITH CROHN'S DISEASE OVER A PERIOD OF 24 WEEKS AND A FOLLOW-UP PERIOD UP TO 52 WEEKS",No,816649795,2021,01/20/2023,NCT03279081,,
8624,UNCHANGED,Covered Recipient Teaching Hospital,,40014.0,10968.0,WHITE COUNTY MEDICAL CENTER,,,,,,,504 W Main St  A,,Bradford,AR,72020,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,713718.0,1316141963.0,JAMES,KYLE,CITTY,,2900 HAWKINS DR,,SEARCY,AR,72143-4802,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology,,,,,,AR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ABBVIE INC.,100000000204,ABBVIE INC.,IL,United States,Yes,Covered,Drug,WOMENS HEALTH,ORILISSA,0074-0038-28,,,,,,,,,,,,,,,,,,,,,,,,,,861.21,04/09/2021,Cash or cash equivalent,,,,,,,No,No,A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain,No,792395307,2021,01/20/2023,NCT03213457,,M14-702
2033,UNCHANGED,Covered Recipient Teaching Hospital,,363305.0,10350.0,Nationwide Childrens Hospital,,,,,,,700 CHILDRENS DR,,COLUMBUS,OH,43205,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1342672.0,1043452378.0,BRIAN,ALAN,BOE,,700 CHILDRENS DR,,COLUMBUS,OH,43205,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pediatrics|Pediatric Cardiology,,,,,,OH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"W. L. Gore & Associates, Inc.",100000010774,"W. L. Gore & Associates, Inc.",DE,United States,Yes,Non-Covered,Device,Devices,Product in Development,,,,,,,,,,,,,,,,,,,,,,,,,,,2145.0,10/01/2021,Cash or cash equivalent,,,,,,,No,No,GORE CARDIOFORM ASD Occluder Clinical Study A Study to evaluate safety and efficacy in the treatment of transcatheter closure of ostium secundum atrial septal defects ASDs,No,831701497,2021,01/20/2023,NCT02985684,,
4705,UNCHANGED,Covered Recipient Teaching Hospital,,260138.0,10619.0,Saint Lukes Hospital Of Kansas City,,,,,,,10918 Elm Ave,,Kansas City,MO,64134,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,225339.0,1982603973.0,JOHN,,SPERTUS,,4320 WORNALL RD,SUITE 65,KANSAS CITY,MO,64111-5941,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease,,,,,,MO,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Janssen Pharmaceuticals, Inc",100000000332,"Janssen Scientific Affairs, LLC",NJ,United States,Yes,Covered,Drug,Cardiovascular & Metabolism,INVOKANA,50458-140-30,,,,,,,,,,,,,,,,,,,,,,,,,,22656.0,09/23/2021,Cash or cash equivalent,,,,,,,Yes,No,,No,787568471,2021,01/20/2023,,,
9479,UNCHANGED,Covered Recipient Teaching Hospital,,54144.0,11286.0,Langley Porter Psychiatric Hospital,,,,,,,401 PARNASSUS AVE,,SAN FRANCISCO,CA,94143,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1212621.0,1831117571.0,KRISTIN,A.,SHIMANO,,550 16th St Fl 4344,,San Francisco,CA,94158,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pediatrics|Pediatric Hematology-Oncology,,,,,,CA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sanofi and Genzyme US Companies,100000771811,PRINCIPIA BIOPHARMA INC.,CA,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4389.0,08/27/2021,Cash or cash equivalent,,,,,,,No,No,"Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)",No,838656039,2021,01/20/2023,NCT04562766,,
4664,UNCHANGED,Covered Recipient Teaching Hospital,,263302.0,10622.0,Childrens Mercy Hospital,,,,,,,2401 GILLHAM RD,,KANSAS CITY,MO,64108,United States,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,United States,Yes,Covered,Device,Transcatheter Heart Valves,EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV),,00690103194357,,,,,,,,,,,,,,,,,,,,,,,,,4500.0,12/06/2021,Cash or cash equivalent,,,,,,,No,No,ALTERRA Early Feasibility (2016-04),No,809685977,2021,01/20/2023,,,
3887,UNCHANGED,Covered Recipient Physician,,,,,303222.0,1679551444.0,BRADLEY,S,GIEDD,,1928 HOWELL BRANCH RD,,WINTER PARK,FL,32792-1013,United States,,,Doctor of Optometry,,,,,,Eye and Vision Services Providers|Optometrist,,,,,,FL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Alcon Research LLC,100000000218,Alcon Research LLC,TX,United States,Yes,Covered,Device,Ophthamology,TOTAL 30,,,,,,,,,,,,,,,,,,,,,,,,,,,412.8,05/05/2021,Cash or cash equivalent,,,,,,,No,No,Clinical Biocompatibility of Three Daily Wear Monthly Replacement Silicone Hydrogel Contact Lenses with Two Multi-purpose Disinfecting Solution Combinations,No,807648563,2021,01/20/2023,,,
6870,UNCHANGED,Covered Recipient Teaching Hospital,,50348.0,11307.0,UCI MEDICAL CENTER,,,,,,,101 The City Dr S,,Orange,CA,92868,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1263308.0,1639259872.0,SAI HONG,I,OU,,200 S MANCHESTER AVE STE 400,,ORANGE,CA,92868,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,CA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Pfizer Inc.,100000000286,PFIZER INC.,NY,United States,Yes,Covered,Drug,ONCOLOGY,LORBRENA,0069-0227-01,,,,,,,,,,,,,,,,,,,,,,,,,,36419.6,08/05/2021,Cash or cash equivalent,,,,,,,No,No,PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS,No,832711863,2021,01/20/2023,,,
9181,UNCHANGED,Covered Recipient Teaching Hospital,,110010.0,10785.0,Emory University Hospital,,,,,,,1821 CLIFTON RD NE,,ATLANTA,GA,30329,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,585635.0,1811160609.0,HONG,,LI,,OFFICE FOR CLINICAL RESEARCH,,ATLANTA,GA,30322,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Medical Genetics|Clinical Genetics (M.D.),,,,,,GA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Moderna TX, Inc.",100000961851,"Moderna TX, Inc.",MA,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1296.0,09/03/2021,Cash or cash equivalent,,,,,,,No,No,"A longitudinal, exploratory, natural history study to further characterize and describe the signs and symptoms of patients with organic acidemias.",No,806342203,2021,01/20/2023,,,
2052,UNCHANGED,Covered Recipient Teaching Hospital,,450076.0,11031.0,Ut Md Anderson Cancer Center,,,,,,,1515 Holcombe Blvd,,Houston,TX,77030,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,603691.0,1447584131.0,EDUARDO,,VILAR SANCHEZ,,1515 HOLCOMBE BLVD,,HOUSTON,TX,77030-4009,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Medical Genetics|Ph.D. Medical Genetics,,,,,,TX,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,99914.0,08/19/2021,Cash or cash equivalent,,,,,,,No,No,A Phase 1b Multi Center Randomized Blinded Placebo controlled Study to Evaluate the Efficacy of Guselkumab in Subjects with Familial Adenomatous Polyposis,No,787602883,2021,01/20/2023,,,
2541,UNCHANGED,Covered Recipient Teaching Hospital,,50625.0,11293.0,Cedars-Sinai Medical Center,,,,,,,8700 Beverly Blvd,,West Hollywood,CA,90048,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,467133.0,1649290248.0,KAREN,,RECKAMP,,1500 E. DUARTE RD,,DUARTE,CA,91010,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,,,,,,CA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30980.0,06/07/2021,Cash or cash equivalent,,,,,,,No,No,An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation EGFRTKI as Monotherapy or in Combinations With JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non Sm,No,787577901,2021,01/20/2023,,,
9949,UNCHANGED,Covered Recipient Teaching Hospital,,460009.0,11165.0,U OF U HOSPITALS & CLINICS,,,,,,,50 N Medical Dr,,Salt Lake City,UT,84132,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,821548.0,1104093392.0,JAMIE,,RHOADS,,4488 HANALEI PLANTATION RD,,PRINCEVILLE,HI,96722,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Dermatology,,,,,,UT,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Pfizer Inc.,100000000286,PFIZER INC.,NY,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10161.76,07/08/2021,Cash or cash equivalent,,,,,,,No,No,A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF06650833 PF06700841 AND PF06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA,No,832544127,2021,01/20/2023,,,
132,UNCHANGED,Covered Recipient Physician,,,,,289088.0,1386738938.0,BARRY,J,REINER,,1001 PINE HEIGHTS AVE,STE 202,BALTIMORE,MD,21229,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pediatrics|Pediatric Endocrinology,,,,,,MD,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,Denmark,Yes,Covered,Drug,Obesity,Saxenda,0169-2800-15,,,,,,,,,,,,,,,,,,,,,,,,,,229.0,07/13/2021,In-kind items and services,,,,,,,No,No,NN8022-4392,No,811831791,2021,01/20/2023,,,
2884,UNCHANGED,Covered Recipient Teaching Hospital,,363303.0,10368.0,Childrens Hospital Medical Center,,,,,,,1 PERKINS SQ,,AKRON,OH,44308,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,5701797.0,1639411788.0,MATTHEW,RUSSELL,GINSBERG,,One Perkins Square,Attn: Maura Freaney,Akron,OH,44308,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology,,,,,,OH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",MA,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,333.75,05/06/2021,Cash or cash equivalent,,,,,,,No,No,"An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Eculizumab in Pediatric Patients With Refractory Generalized Myasthenia Gravis",No,781383465,2021,01/20/2023,NCT03759366,,
3451,UNCHANGED,Covered Recipient Teaching Hospital,,220162.0,9984.0,DANA-FARBER CANCER INSTITUTE,,,,,,,450 Brookline Ave,,Boston,MA,02215,United States,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000337,"Takeda Pharmaceuticals U.S.A., Inc.",IL,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,71200.0,05/18/2021,Cash or cash equivalent,,,,,,,Yes,No,,No,816654127,2021,01/20/2023,,,
2446,UNCHANGED,Covered Recipient Teaching Hospital,,390111.0,10224.0,Hospital Of The Univ Of Penna,,,,,,,3400 Spruce Street,,Philadelphia,PA,19104,United States,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Amicus Therapeutics, Inc.",100000381810,"Amicus Therapeutics, Inc.",PA,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,488920.73,10/01/2021,Cash or cash equivalent,,,,,,,Yes,No,PRE-CLINICAL GENE THERAPY / LYSOSOMAL STORAGE DISORDER,No,850489693,2021,01/20/2023,,,
550,UNCHANGED,Covered Recipient Teaching Hospital,,100007.0,10819.0,Adventhealth Orlando,,,,,,,601 E Rollins St,,Orlando,FL,32803,United States,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,27165.0,03/29/2021,Cash or cash equivalent,,,,,,,No,No,COVID-19 Phase 3 Vaccine Trial Readiness Cohorts - Advent Health Orlando,No,787574791,2021,01/20/2023,,,
1718,UNCHANGED,Covered Recipient Teaching Hospital,,450076.0,11031.0,UT MD ANDERSON CANCER CENTER,,,,,,,1515 Holcombe Blvd,,Houston,TX,77030,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,189527.0,1174726384.0,VIVEK,,SUBBIAH,,1515 HOLCOMBE BLVD,,HOUSTON,TX,77030,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,,,,,,TX,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Pfizer Inc.,100000000286,PFIZER INC.,NY,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,21822.73,08/21/2021,Cash or cash equivalent,,,,,,,No,No,A TWOPART PHASE 1AB OPENLABEL MULTICENTER TRIAL EVALUATING PHARMACOKINETICS SAFETY AND EFFICACY OF PF 07284890 ARRY 461 IN PARTICIPANTS WITH BRAF V600 MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT,No,832903671,2021,01/20/2023,,,
8017,UNCHANGED,Covered Recipient Physician,,,,,289088.0,1386738938.0,BARRY,J,REINER,,1001 PINE HEIGHTS AVE,STE 202,BALTIMORE,MD,21229,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pediatrics|Pediatric Endocrinology,,,,,,MD,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,Denmark,Yes,Covered,Drug,Obesity,Saxenda,0169-2800-15,,,,,,,,,,,,,,,,,,,,,,,,,,9.98,07/13/2021,In-kind items and services,,,,,,,No,No,NN8022-4392,No,811831793,2021,01/20/2023,,,
5812,UNCHANGED,Covered Recipient Physician,,,,,139127.0,1073519989.0,VANCE,M,THOMPSON,,3101 W 57TH ST,,SIOUX FALLS,SD,57108,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Ophthalmology,,,,,,SD,ND,IA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RxSight Inc,100000676811,RxSight Inc,CA,United States,Yes,Covered,Device,Ophthalmology,LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD),,,,,,,,,,,,,,,,,,,,,,,,,,,5780.0,03/04/2021,Cash or cash equivalent,,,,,,,No,No,CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFECTIVENESS OF THE RXSIGHT LIGHT ADJUSTABLE LENS (LAL) IN SUBJECTS DESIRING AN EXTENDED DEPTH OF FOCUS,No,854610463,2021,01/20/2023,NCT04177771,,"Evaluate, for the visual correction of aphakia and presbyopia, the safety and effectiveness of the RxSight Light Adjustable Lens (LAL) to provide an extended depth of focus (improve intermediate and near visual acuity without compromising distance visual acuity) in subjects who have undergone bilateral implantation with the LAL and subsequent light treatments for refractive and presbyopia correction (LAL group)."
335,UNCHANGED,Covered Recipient Teaching Hospital,,390111.0,10224.0,Hospital Of The Univ Of Penna,,,,,,,3701 MARKET ST,,PHILA,PA,19104,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,347595.0,1669458287.0,DAVID,S.,FRANKEL,,145 King Of Prussia Rd,Ste 110s,RADNOR,PA,19087,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Clinical Cardiac Electrophysiology,,,,,,PA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,United States,Yes,Covered,Device,Implantable Cardioverter Defibrillators (ICDs),Viva,,00643169720312,,,,,,,,,,,,,,,,,,,,,,,,,1902.0,07/12/2021,Cash or cash equivalent,,,,,,,No,No,AdaptResponse,No,801000027,2021,01/20/2023,,,
7769,UNCHANGED,Covered Recipient Physician,,,,,117983.0,1598924995.0,JULIUS,M,WILDER,,2301 ERWIN RD,,DURHAM,NC,27705,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine,,,,,,NC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,Denmark,Yes,Covered,Drug,Obesity,Wegovy,0169-4525-14,,,,,,,,,,,,,,,,,,,,,,,,,,100.0,05/14/2021,Cash or cash equivalent,,,,,,,No,No,EX9536-4388,No,811307815,2021,01/20/2023,,,
1430,UNCHANGED,Covered Recipient Physician,,,,,7979.0,1184627333.0,RAJESH,,DAVE,,9 SAND PINE CT,,MECHANICSBURG,PA,17050,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease,,,,,,PA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"MicroVention, Inc.",100000010928,"MicroVention, Inc.",CA,United States,Yes,Covered,Device,Neurological Product,HydroCoil Helical,,00812636021409,,,,,,,,,,,,,,,,,,,,,,,,,15147.5,06/04/2021,Cash or cash equivalent,,,,,,,Yes,No,,No,843596639,2021,01/20/2023,,,
2721,UNCHANGED,Covered Recipient Teaching Hospital,,420027.0,10777.0,Anmed Health,,,,,,,800 N FANT ST,,ANDERSON,SC,29621,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,260312.0,1740266725.0,BRENT,TINDAL,MCLAURIN,,100 PERPETUAL SQ,,ANDERSON,SC,29621,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease,,,,,,GA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,United States,Yes,Covered,Device,Cardiology/Vascular Diseases,Orsiro,,07640130455948,,,,,,,,,,,,,,,,,,,,,,,,,48.75,07/13/2021,Cash or cash equivalent,,,,,,,No,No,BIOFLOW-VII,No,843833975,2021,01/20/2023,,,
6830,UNCHANGED,Covered Recipient Teaching Hospital,,220110.0,9985.0,Brigham And Womens Hospital,,,,,,,75 FRANCIS ST,,BOSTON,MA,02115,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,306715.0,1750371480.0,PINAK,B.,SHAH,,75 Francis St,,Boston,MA,02115,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology,,,,,,MA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3175.69,10/18/2021,Cash or cash equivalent,,,,,,,No,No,Partner3 2015-08,No,809689401,2021,01/20/2023,,,
7921,UNCHANGED,Covered Recipient Teaching Hospital,,140119.0,10441.0,RUSH UNIVERSITY MEDICAL CENTER,,,,,,,1653 W CONGRESS PKWY,,CHICAGO,IL,60612,United States,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,United States,Yes,Covered,Biological,BioOncology,Avastin,50242-061-01,,Covered,Biological,BioOncology,TECENTRIQ,50242-917-01,,,,,,,,,,,,,,,,,,,,750.0,05/19/2021,Cash or cash equivalent,,,,,,,No,No,PH2 STUDY OF ATEZOLIZUMAB WITH OR W O BEVACIZUMAB,No,835924411,2021,01/20/2023,,,
6775,UNCHANGED,Covered Recipient Teaching Hospital,,230046.0,10547.0,UNIV OF MI HOSPITALS & HLTH CTRS,,,,,,,1500 EAST MEDICAL CENTER DRIVE,,ANN ARBOR,MI,48109,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,263157.0,1801993167.0,PAUL,,PARK,,1500 EAST MEDICAL CENTER DR,2ND FLOOR TAUBMAN CTR RECP G,ANN ARBOR,MI,48109-5338,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Neurological Surgery,,,,,,MI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"SI-BONE, INC.",100000011102,"SI-BONE, Inc.",CA,United States,Yes,Covered,Device,SACROILIAC JOINT DYSFUNCTION,IFUSE IMPLANT,,,,,,,,,,,,,,,,,,,,,,,,,,,645.0,11/19/2021,Cash or cash equivalent,,,,,,,No,No,SILVIA,No,845529759,2021,01/20/2023,,,
4970,UNCHANGED,Covered Recipient Physician,,,,,60796.0,1356421515.0,TAHSEEN,,MOZAFFAR,,200 S Manchester Ave Ste 110,,Orange,CA,92868,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology,,,,,,CA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sanofi and Genzyme US Companies,100000000297,GENZYME CORPORATION,MA,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,250.0,05/21/2021,In-kind items and services,,,,,,,No,No,"A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatment-naive Patients With Late-onset Pompe Disease",No,838655751,2021,01/20/2023,NCT02782741,,Transfer of value represents in-kind publication support services and does not reflect any actual monetary transfer of value to the Covered Recipient.
9823,UNCHANGED,Covered Recipient Teaching Hospital,,230038.0,10508.0,Spectrum Health  Hospitals,,,,,,,100 Michigan St Ne,,Grand Rapids,MI,49503,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,879336.0,1134339369.0,Beng,Richard,Fuh,,600 Moye Blvd,,Greenville,NC,27834,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pediatrics,,,,,,NC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,United States,Yes,Covered,Drug,Thrombosis,SAVAYSA,65597-201-07,,,,,,,,,,,,,,,,,,,,,,,,,,26.85,07/09/2021,Cash or cash equivalent,,,,,,,No,No,DU176b-D-U312,No,835064789,2021,01/20/2023,NCT02798471,,
6724,UNCHANGED,Covered Recipient Teaching Hospital,,440039.0,10425.0,VANDERBILT UNIVERSITY MEDICAL CENTER,,,,,,,1211 MEDICAL CENTER DRIVE,,NASHVILLE,TN,37232,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,316238.0,1972657609.0,MICHAEL,,FROEHLER,,1211 MEDICAL CENTER DR,,NASHVILLE,TN,37232,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Radiology|Neuroradiology,,,,,,CA,IA,TN,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,United States,Yes,Non-Covered,Drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11659.14,03/17/2021,Cash or cash equivalent,,,,,,,No,No,TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS,No,835933715,2021,01/20/2023,,,
3173,UNCHANGED,Covered Recipient Teaching Hospital,,60010.0,11138.0,Poudre Valley Hospital,,,,,,,2121 E HARMONY RD UNIT 200,,FORT COLLINS,CO,80528,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1303361.0,1083660708.0,DIANA,,MEDGYESY,,2121 E Harmony Rd,,FORT COLLINS,CO,80528,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,CO,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Seagen Inc.,100000000279,Seagen Inc.,WA,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1430.0,09/15/2021,Cash or cash equivalent,,,,,,,No,No,"A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer",No,792655779,2021,01/20/2023,NCT01969643,https://clinicaltrials.gov/ct2/show/NCT01969643,
4830,UNCHANGED,Covered Recipient Teaching Hospital,,393303.0,10215.0,THE CHILDRENS HOSPITAL OF PHILADELP,,,,,,,34TH STREET & CIVIC CENTER BLVD,,PHILADELPHIA,PA,19104,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,242736.0,1346407558.0,JOSEPH,,ROSSANO,,3401 CIVIC CENTER BLVD,CHILDREN S HOSPITAL OF PHILADELPHIA  CARDIOLOGY,PHILADELPHIA,PA,19104-4319,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pediatrics|Pediatric Cardiology,,,,,,PA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Novartis Pharmaceuticals Corporation,100000000228,Novartis Pharmaceuticals Corporation,NJ,United States,Yes,Covered,Drug,CARDIOVASCULAR,ENTRESTO,0078-0659-20,,,,,,,,,,,,,,,,,,,,,,,,,,17529.13,01/27/2021,Cash or cash equivalent,,,,,,,No,No,A MULTICENTER STUDY TO EVALUATE SAFETY AND TOLERABILITY OF OPEN LABEL LCZ696 IN PEDIATRIC HEART FAILURE PATIENTS WHO HAVE SUCCESSFULLY COMPLETED THE PANORAMA HF STUDY A,No,800616809,2021,01/20/2023,,,
514,UNCHANGED,Covered Recipient Teaching Hospital,,130006.0,11100.0,ST. LUKES REGIONAL MEDICAL CENTER,,,,,,,190 E BANNOCK ST,,BOISE,ID,83712,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,73913.0,1629117619.0,KAREN,S,MILLER,,2347 E GALA ST,,MERIDIAN,ID,83642,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease,,,,,,ID,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Genentech, Inc.",100000005726,Hoffmann-La Roche Limited,,Canada,Yes,Covered,Biological,Immunology,Actemra,50242-137-01,,,,,,,,,,,,,,,,,,,,,,,,,,15.03,05/25/2021,Cash or cash equivalent,,,,,,,No,No,SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA,No,835926429,2021,01/20/2023,,,
499,UNCHANGED,Covered Recipient Teaching Hospital,,390028.0,10267.0,Upmc Mercy Hospital,,,,,,,1400 Locust St,,Pittsburgh,PA,15219,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,347278.0,1649242033.0,SILVA,A,ARSLANIAN,,5230 CENTRE AVE,FL 2,PITTSBURGH,PA,15232,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine,,,,,,PA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,Denmark,Yes,Non-Covered,Drug,Diabetes,,,,,,,,,,,,,,,,,,,,,,,,,,,,55.54,05/26/2021,In-kind items and services,,,,,,,No,No,NN9536-4451,No,811451619,2021,01/20/2023,,,
8917,UNCHANGED,Covered Recipient Teaching Hospital,,130006.0,11100.0,ST. LUKES REGIONAL MEDICAL CENTER,,,,,,,190 E BANNOCK ST,,BOISE,ID,83712,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,122524.0,1710914528.0,DAVID,A,HINCHMAN,,300 E JEFFERSON ST STE 101,,BOISE,ID,83712,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease,,,,,,ID,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1119.86,06/25/2021,In-kind items and services,,,,,,,No,No,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION AND OBESITY (SUMMIT",No,819448857,2021,01/20/2023,NCT04847557,https://clinicaltrials.gov/ct2/show/NCT04847557,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor"
4030,UNCHANGED,Covered Recipient Teaching Hospital,,143300.0,10439.0,ANN & ROBERT H. LURIE CHILDRENS HOS,,,,,,,1121 Techny Rd,,Northbrook,IL,60062,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,613576.0,1790896041.0,WILLIAM,J,MULLER,,225 E CHICAGO AVE,BOX 20,CHICAGO,IL,60611-2991,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pediatrics|Pediatric Infectious Diseases,,,,,,IL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Astellas US Technologies,100000005408,Astellas US Technologies,IL,United States,Yes,Covered,Drug,HOSPITAL AND TRANSPLANT,CRESEMBA,0469-0420-99,,,,,,,,,,,,,,,,,,,,,,,,,,324.85,11/03/2021,In-kind items and services,,,,,,,No,No,"A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects",No,775053547,2021,01/20/2023,,,
5983,UNCHANGED,Covered Recipient Teaching Hospital,,500008.0,11198.0,UNIVERSITY OF WASHINGTON MED CTR,,,,,,,1959 Ne Pacific St,,Seattle,WA,98195,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1199677.0,1386619500.0,VEENA,,SHANKARAN,,825 EASTLAKE AVE E,825 EASTLAKE AVE E,SEATTLE,WA,98109-4405,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,,,,,,WA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,United States,Yes,Covered,Biological,ONCOLOGY,KEYTRUDA,0006-3029-02,,,,,,,,,,,,,,,,,,,,,,,,,,2784.44,12/31/2021,In-kind items and services,,,,,,,No,No,A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Flourouracil in Subjects with Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma,No,848743667,2021,01/20/2023,,,
5367,UNCHANGED,Covered Recipient Teaching Hospital,,100271.0,10837.0,MOFFITT CANCER CENTER,,,,,,,12902 Magnolia Dr,,Tampa,FL,33612,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,360901.0,1942266929.0,RAMI,S,KOMROKJI,,222 PIEDMONT AVE,STE STE 4000,CINCINNATI,OH,45219-4231,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,,,,,,FL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000337,"Takeda Pharmaceuticals U.S.A., Inc.",IL,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,135.0,07/01/2021,Cash or cash equivalent,,,,,,,No,No,"A PHASE 2, RANDOMIZED, CONTROLLED, OPEN-LABEL, CLINICAL STUDY OF THE EFFICACY AND SAFETY OF PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA AND LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA",No,816661997,2021,01/20/2023,,,
4508,UNCHANGED,Covered Recipient Teaching Hospital,,360085.0,10339.0,THE OHIO STATE UNIVERSITY HOSPITAL,,,,,,,1670 Upham Dr,,Columbus,OH,43210,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1062167.0,1558453977.0,DAVID,P,CARBONE,,460 W 10TH AVE,,COLUMBUS,OH,43210-1240,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,OH,,,,,Covered Recipient Physician,762901.0,1033119896.0,PETER,,SHIELDS,,460 W 10TH AVE,,COLUMBUS,OH,43210-1240,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,,,,,,OH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Foundation Medicine, Inc.",100000191782,"Foundation Medicine, Inc.",MA,United States,Yes,Covered,Device,ONCOLOGY,FOUNDATIONONE CDX,,,,,,,,,,,,,,,,,,,,,,,,,,,1500.0,11/30/2021,In-kind items and services,,,,,,,No,No,F1CDX-AMC-PRO-19-1983,No,799850353,2021,01/20/2023,,,
5051,UNCHANGED,Covered Recipient Teaching Hospital,,220086.0,9982.0,BETH ISRAEL DEACONESS MEDICAL CENTER,,,,,,,330 Brookline Ave,St 207,Boston,MA,02215,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,88160.0,1942259098.0,ROBERT,I,HADDAD,,44 BINNEY ST,44 BINNEY ST,BOSTON,MA,02115,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,,,,,,MA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,United States,Yes,Covered,Biological,ONCOLOGY,KEYTRUDA,0006-3029-02,,,,,,,,,,,,,,,,,,,,,,,,,,27238.71,12/31/2021,In-kind items and services,,,,,,,No,No,A Phase II Clinical Trial of Single Agent Pembrolizumab MK-3475 in Subjects with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma HNSCC Who Have Failed Platinum and Cetuximab,No,848743979,2021,01/20/2023,,,
492,UNCHANGED,Covered Recipient Teaching Hospital,,363300.0,10334.0,CHILDRENS HOSPITAL MEDICAL CENTER,,,,,,,3333 BURNET AVE,,CINCINNATI,OH,45229,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,658528.0,1366491821.0,AMAL,H,ASSAAD,,3333 BURNET AVE,ML 2000,CINCINNATI,OH,45229-3039,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pediatrics|Pediatric Allergy/Immunology,,,,,,OH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"AIMMUNE THERAPEUTICS, INC.",100000776814,"AIMMUNE THERAPEUTICS, INC.",CA,United States,Yes,Covered,Biological,ALLERGY,PALFORZIA,71881-113-13,,,,,,,,,,,,,,,,,,,,,,,,,,438.0,05/11/2021,Cash or cash equivalent,,,,,,,No,No,"A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY",No,849613223,2021,01/20/2023,,,
1509,UNCHANGED,Covered Recipient Physician,,,,,191380.0,1235127713.0,CLAYTON,GREGG,BLEHM,,2061 BEVERLY RD,,GAINESVILLE,GA,30501-2034,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Ophthalmology,,,,,,GA,NC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Alcon Research LLC,100000000218,Alcon Research LLC,TX,United States,Yes,Covered,Device,Ophthalmology,AcrySof IQ PanOptix,,00380652429436,,,,,,,,,,,,,,,,,,,,,,,,,32250.0,04/29/2021,Cash or cash equivalent,,,,,,,No,No,Spectacle Freedom and Patient Satisfaction with Bilateral Alcon PanOptix IOLs,No,807646755,2021,01/20/2023,,,
9284,UNCHANGED,Covered Recipient Teaching Hospital,,450076.0,11031.0,Ut Md Anderson Cancer Center,,,,,,,1515 HOLCOMBE BLVD,,HOUSTON,TX,77030,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,2777165.0,1841733102.0,JORDI,,RODON AHNERT,,1515 HOLCOMBE BLVD,UNIT 455,HOUSTON,TX,77030,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,,,,,,TX,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Incyte Corporation,100000000263,Incyte Corporation,DE,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.3,03/08/2021,Cash or cash equivalent,,,,,,,No,No,"A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)",No,831074745,2021,01/20/2023,,,"Payments or transfers of value related to research are provided to a studys respective site and associated, per CMS requirements, with a Principal Investigator. The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and study drug."
187,UNCHANGED,Covered Recipient Teaching Hospital,,100069.0,10824.0,Adventhealth Carrollwood,,,,,,,7171 N DALE MABRY HWY,,TAMPA,FL,33614,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,118841.0,1619291994.0,PAUL,Z.,GERCZUK,,14320 BRUCE B DOWNS BLVD,,TAMPA,FL,33613,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Clinical Cardiac Electrophysiology,,,,,,FL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,United States,Yes,Covered,Device,Cardiology/Vascular Diseases,Acticor,,04035479156701,Covered,Device,Cardiology/Vascular Diseases,Solia,,04035479118266,Covered,Device,Cardiology/Vascular Diseases,Rivacor,,04035479156794,Covered,Device,Cardiology/Vascular Diseases,Plexa,,4035479140014.0,Covered,Device,Cardiology/Vascular Diseases,Sentus,,4035479148942.0,50.0,12/14/2021,Cash or cash equivalent,,,,,,,No,No,BIO-LIBRA,No,843814579,2021,01/20/2023,,,
5251,UNCHANGED,Covered Recipient Teaching Hospital,,223302.0,9992.0,CHILDRENS HOSPITAL CORPORATION,,,,,,,300 Longwood Ave,Patient Financial Services Atn Steven Nicoll,Boston,MA,02115,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,296783.0,1538191309.0,BASIL,T,DARRAS,,300 LONGWOOD AVE,FEGAN 11,BOSTON,MA,02115-5724,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology with Special Qualifications in Child Neurology,,,,,,MA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"PTC Therapeutics, Inc.",100000191753,"PTC Therapeutics, Inc.",NJ,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1732.5,08/03/2021,Cash or cash equivalent,,,,,,,No,No,"AN OPEN-LABEL, SAFETY STUDY FOR PREVIOUSLY TREATED ATALUREN PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY",No,849319511,2021,01/20/2023,NCT01247207,,
5376,UNCHANGED,Covered Recipient Teaching Hospital,,360180.0,10373.0,Cleveland Clinic Hospital,,,,,,,9500 Euclid Ave,,Cleveland,OH,44195,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1294466.0,1811284458.0,Shrif,Joseph,Costandi,,9500 Euclid Ave,,Cleveland,OH,44195-0001,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,,,,,,OH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Vertos Medical, Inc.",100000016247,"Vertos Medical, Inc.",CA,United States,Yes,Covered,Device,Orthopedic,mild Device Kit,,B235MDK00010,,,,,,,,,,,,,,,,,,,,,,,,,900.0,09/01/2021,Cash or cash equivalent,,,,,,,No,No,The MOTION Study,No,841914995,2021,01/20/2023,NCT03610737,,
6822,UNCHANGED,Covered Recipient Physician,,,,,902000.0,1932144573.0,MAZEN,M.,DIMACHKIE,,3599 Rainbow Blvd,,Kansas City,KS,66103,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology,,,,,,KS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sanofi and Genzyme US Companies,100000000297,GENZYME CORPORATION,MA,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,250.0,06/19/2021,In-kind items and services,,,,,,,No,No,"A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatment-naive Patients With Late-onset Pompe Disease",No,838654359,2021,01/20/2023,NCT02782741,,Transfer of value represents in-kind publication support services and does not reflect any actual monetary transfer of value to the Covered Recipient.
2090,UNCHANGED,Covered Recipient Teaching Hospital,,260108.0,10606.0,Missouri Baptist Medical Center,,,,,,,3015 N Ballas Rd,,Saint Louis,MO,63131,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,2252.0,1053401422.0,GUS,,THEODOS,,3023 N BALLAS RD STE 200D,,SAINT LOUIS,MO,63131,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology,,,,,,MO,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Penumbra, Inc.",100000010583,"Penumbra, Inc.",CA,United States,Yes,Covered,Device,Peripheral Intervention,Indigo System,,00814548017556,,,,,,,,,,,,,,,,,,,,,,,,,600.0,09/09/2021,Cash or cash equivalent,,,,,,,No,No,CHEETAH,No,840452245,2021,01/20/2023,,,
9864,UNCHANGED,Covered Recipient Teaching Hospital,,100006.0,10829.0,Orlando Health,,,,,,,1414 Kuhl Ave,,Orlando,FL,32806,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,328598.0,1235334301.0,VIJAYKUMAR,,KASI,,1222 S ORANGE AVE,,ORLANDO,FL,32806-1215,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology,,,,,,FL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Abbott Laboratories,100000010680,Abbott Laboratories,IL,United States,Yes,Covered,Device,Vascular,Dragonfly OCT,,05415067031129,,,,,,,,,,,,,,,,,,,,,,,,,1900.0,01/21/2021,Cash or cash equivalent,,,,,,,No,No,Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow Percutaneous Left Ventricular Support Device (SHIELD II),No,827568445,2021,01/20/2023,,,
4049,UNCHANGED,Covered Recipient Teaching Hospital,,30103.0,11162.0,Mayo Clinic Hospital,,,,,,,5777 E Mayo Blvd,,Phoenix,AZ,85054,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,99320.0,1194961763.0,PARMINDER,,SINGH,,13400 E SHEA BLVD,,SCOTTSDALE,AZ,85259,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,AZ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,United States,Yes,Covered,Drug,Oncology,CABOMETYX,42388-023-26,,,,,,,,,,,,,,,,,,,,,,,,,,390.0,01/26/2021,Cash or cash equivalent,,,,,,,No,No,Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,No,838849989,2021,01/20/2023,NCT03170960,,
6836,UNCHANGED,Covered Recipient Teaching Hospital,,450076.0,11031.0,Ut Md Anderson Cancer Center,,,,,,,1515 Holcombe Blvd,,Houston,TX,77030,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,830376.0,1417211368.0,GREGORY,,KAUFMAN,,1515 HOLCOMBE BLVD,,HOUSTON,TX,77030,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,TX,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11731.82,11/01/2021,Cash or cash equivalent,,,,,,,No,No,A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant,No,787602927,2021,01/20/2023,,,
1178,UNCHANGED,Covered Recipient Teaching Hospital,,230297.0,10146.0,Karmanos Cancer Hospital,,,,,,,4100 John R St,,Detroit,MI,48201,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1376785.0,1407112162.0,ANDREW,,KIN,,4100 JOHN R ST,,DETROIT,MI,48201-2013,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology,,,,,,MI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6711.6,03/15/2021,Cash or cash equivalent,,,,,,,No,No,A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subjects with Relapsed or Refractory Multiple Myeloma,No,787585841,2021,01/20/2023,,,
7429,UNCHANGED,Covered Recipient Teaching Hospital,,50625.0,11293.0,Cedars-Sinai Medical Center,,,,,,,8700 Beverly Blvd,,West Hollywood,CA,90048,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,467133.0,1649290248.0,KAREN,,RECKAMP,,1500 E. DUARTE RD,,DUARTE,CA,91010,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,,,,,,CA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5171.64,11/25/2021,Cash or cash equivalent,,,,,,,No,No,An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation EGFRTKI as Monotherapy or in Combinations With JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non Sm,No,787577937,2021,01/20/2023,,,
3714,UNCHANGED,Covered Recipient Physician,,,,,386382.0,1811944481.0,KATHLEEN,M,DOISY,,3217 S PROVIDENCE RD,,COLUMBIA,MO,65203-3639,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pediatrics,,,,,,MO,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Banner Life Sciences, LLC",100000116366,"Banner Life Sciences, LLC",NC,United States,Yes,Covered,Drug,Immune,BAFIERTAM,69387-001-01,,,,,,,,,,,,,,,,,,,,,,,,,,176020.0,02/04/2021,Cash or cash equivalent,Professional Salary Support,,,,,,No,No,GI TOLERABILITY STUDY,No,844345921,2021,01/20/2023,NCT05181215,https://clinicaltrials.gov/ct2/show/NCT05181215,"COMBINED CLINICAL AND MED AFFAIRS WORK, GI TOLERABILITY STUDY PORTION"
5918,UNCHANGED,Covered Recipient Teaching Hospital,,160058.0,10604.0,UNIVERSITY OF IOWA HOSP & CLINICS,,,,,,,200 Hawkins Dr,,Iowa City,IA,52242,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,588774.0,1932141660.0,STEVEN,F,POLYAK,,200 HAWKINS DR  4574,,IOWA CITY,IA,52242,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology,,,,,,IA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Pfizer Inc.,100000000286,PFIZER INC.,NY,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5173.5,02/23/2021,Cash or cash equivalent,,,,,,,No,No,A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS,No,832858073,2021,01/20/2023,,,
2629,UNCHANGED,Covered Recipient Teaching Hospital,,220162.0,9984.0,Dana-Farber Cancer Institute,,,,,,,450 Brookline Ave,,Boston,MA,02215,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,329119.0,1255309316.0,GEOFFREY,I,SHAPIRO,,450 BROOKLINE AVE   M446,,BOSTON,MA,02215-5418,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,,,,,,MA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Boehringer Ingelheim USA, Inc.",100000010530,SCS Boehringer Ingelheim Comm.V,,Belgium,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,146.7,08/01/2021,In-kind items and services,,,,,,,No,No,Phase I dose escalation FIM,No,827029139,2021,01/20/2023,,,
7016,UNCHANGED,Covered Recipient Teaching Hospital,,50696.0,11289.0,Keck Hospital Of Usc,,,,,,,1500 SAN PABLO STREET,,LOS ANGELES,CA,90033,United States,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CSL Behring,100000005563,CSL Behring,PA,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,18784.0,09/30/2021,Cash or cash equivalent,,,,,,,No,No,Costs of Illness and Impact of von Willebrand Disease: A Pilot Study,No,819680343,2021,01/20/2023,,,
9578,UNCHANGED,Covered Recipient Teaching Hospital,,53302.0,11301.0,Childrens Hospital Los Angeles,,,,,,,4650 W Sunset Blvd,,Los Angeles,CA,90027,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1146597.0,1508031352.0,LILY,,CHAO,,3701 WILSHIRE BLVD,,LOS ANGELES,CA,90010,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pediatrics|Pediatric Endocrinology,,,,,,CA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,Denmark,Yes,Covered,Drug,Diabetes,RYBELSUS,0169-4303-13,,,,,,,,,,,,,,,,,,,,,,,,,,2.85,11/19/2021,In-kind items and services,,,,,,,No,No,NN9924-4437,No,811628153,2021,01/20/2023,,,
4101,UNCHANGED,Covered Recipient Physician,,,,,317125.0,1992740278.0,RAJINDER,,SHIWACH,,1008 YORK DR,,DESOTO,TX,75115,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry,,,,,,TX,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Eli Lilly and Company,100000000088,Eli Lilly and Company,IN,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1404.0,07/02/2021,Cash or cash equivalent,,,,,,,No,No,"ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE",No,819446279,2021,01/20/2023,NCT04437511,https://www.clinicaltrials.gov/ct2/show/NCT04437511,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor"
2276,UNCHANGED,Covered Recipient Physician,,,,,234938.0,1174682090.0,LAZARO,DELA CARIDAD,NUNEZ,,11880 SW 40TH ST STE 405,,MIAMI,FL,33175,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pediatrics,,,,,,FL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ichnos Sciences Inc.,100000806847,Ichnos Sciences Inc.,NY,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2350.0,01/07/2021,Cash or cash equivalent,,,,,,,No,No,GBR830-204,No,834357077,2021,01/20/2023,,,GBR830-204
3895,UNCHANGED,Covered Recipient Teaching Hospital,,220110.0,9985.0,Brigham And Womens Hospital,,,,,,,75 Francis St,,Boston,MA,02115,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,116914.0,1588748883.0,VANITA,R,ARODA,,221 LONGWOOD AVE,# RFB-2,BOSTON,MA,02115,United States,,,Medical Doctor,,,,,,"Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism",,,,,,CA,MA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,Denmark,Yes,Covered,Drug,Diabetes,Ozempic,0169-4132-12,,,,,,,,,,,,,,,,,,,,,,,,,,18.0,03/19/2021,In-kind items and services,,,,,,,No,No,NN9535-4352,No,811851585,2021,01/20/2023,,,
851,UNCHANGED,Covered Recipient Teaching Hospital,,160058.0,10604.0,UNIVERSITY OF IOWA HOSP & CLINICS,,,,,,,200 Hawkins Dr,,Iowa City,IA,52242,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,570344.0,1306090220.0,MUHAMMAD,,FURQAN,,200 HAWKINS DR,DEPT OF INTERNAL MEDICINE C-32 GH,IOWA CITY,IA,52242-1009,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology,,,,,,IA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ABBVIE INC.,100000000204,ABBVIE INC.,IL,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10837.26,03/02/2021,Cash or cash equivalent,,,,,,,No,No,A Phase I Study of ABBV-011 as a Single-Agent and in Combination with Budigalimab (ABBV-181) in Subjects with Relapsed or Refractory Small Cell Lung Cancer,No,792391201,2021,01/20/2023,NCT03639194,,M17-327
6728,UNCHANGED,Covered Recipient Teaching Hospital,,330285.0,10135.0,Strong Memorial Hospital,,,,,,,601 Elmwood Ave,Box 684,Rochester,NY,14642,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,4987253.0,1235493594.0,AJAY,,DHAKAL,,601 ELMWOOD AVE # 704,,ROCHESTER,NY,14642,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,NY,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,AstraZeneca Pharmaceuticals LP,100000010370,AstraZeneca UK Limited,,Great Britain (Uk),Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,19538.0,06/17/2021,Cash or cash equivalent,,,,,,,No,No,"A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib  Fulvestrant Versus Placebo  Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor (CAPItello-291)",No,826482181,2021,01/20/2023,,,
1666,UNCHANGED,Covered Recipient Teaching Hospital,,100271.0,10837.0,Moffitt Cancer Center,,,,,,,12902 Magnolia Dr,,Tampa,FL,33612,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,6130378.0,1992096028.0,MICHAEL,RAHMAN,SHAFIQUE,,12902 USF MAGNOLIA DR,,TAMPA,FL,33612,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,FL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Pfizer Inc.,100000000286,PFIZER INC.,NY,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,19014.75,10/06/2021,In-kind items and services,,,,,,,No,No,A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF SASANLIMAB COMBINED WITH ANTICANCER THERAPIES TARGETING MULTIPLE MOLECULAR MECHANISMS IN PARTICIPANTS WITH NONSMALL CELL LUNG CANCER NSCLC,No,832578195,2021,01/20/2023,,,Study Drug
8534,UNCHANGED,Covered Recipient Teaching Hospital,,310001.0,10178.0,Hackensack University Medical Center,,,,,,,30 PROSPECT AVE,,HACKENSACK,NJ,07601,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,206058.0,1558562793.0,MARTIN,E.,GUTIERREZ,,7650 River Rd Fl 2,,North Bergen,NJ,07047,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,,,,,,FL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bristol Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,161504.12,03/10/2021,Cash or cash equivalent,,,,,,,No,No,Phase I IIA FIH OX40 Mono I-O Combo UBI VAC Part 9,No,819887089,2021,01/20/2023,,,
9564,UNCHANGED,Covered Recipient Physician,,,,,1458973.0,1306139597.0,TIFFANY,L.,FISHER,,30 HOPE DR # EC037,,HERSHEY,PA,17033-2036,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology,,,,,,NC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NEUROPACE, INC.",100000010697,"NEUROPACE, INC.",CA,United States,Yes,Covered,Device,Epilepsy,RNS System,,00855547005267,,,,,,,,,,,,,,,,,,,,,,,,,425.0,10/03/2021,Cash or cash equivalent,,,,,,,No,No,Post Approval Study,No,851400431,2021,01/20/2023,,,
4708,UNCHANGED,Covered Recipient Teaching Hospital,,390006.0,10257.0,Geisinger Medical Center,,,,,,,15 Wesner Ln Fl 2,,Danville,PA,17821,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,169276.0,1710935739.0,CHRISTOPHER,D,STILL,,101 N ACADEMY AVE,,DANVILLE,PA,17822,United States,,,Doctor of Osteopathy,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine,,,,,,PA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,Denmark,Yes,Non-Covered,Drug,Diabetes,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.45,11/18/2021,In-kind items and services,,,,,,,No,No,EX9536-4388,No,811482355,2021,01/20/2023,,,
5941,UNCHANGED,Covered Recipient Teaching Hospital,,230297.0,10146.0,Karmanos Cancer Hospital,,,,,,,4100 JOHN R ST,,DETROIT,MI,48201,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,150282.0,1316985484.0,PHILIP,AGOP,PHILIP,,2800 W GRAND BLVD,,DETROIT,MI,48202,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,,,,,,MI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Incyte Corporation,100000000263,Incyte Corporation,DE,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,21.4,01/11/2021,Cash or cash equivalent,,,,,,,No,No,"A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT 302)",No,831055979,2021,01/20/2023,,,"Payments or transfers of value related to research are provided to a studys respective site and associated, per CMS requirements, with a Principal Investigator. The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and study drug."
6250,ADD,Covered Recipient Teaching Hospital,,250001.0,10938.0,University Of Mississippi Medical,,,,,,,2500 N STATE ST,,JACKSON,MS,39216,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,72184.0,1609810894.0,GAILEN,D.,MARSHALL,,1421 N State St,,Jackson,MS,39202-1658,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Allergy & Immunology,,,,,,MS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CSL Behring,100000005563,CSL Behring,PA,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,70.0,06/16/2021,Cash or cash equivalent,,,,,,,No,No,"A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19)",No,819680623,2021,01/20/2023,NCT04409509,,
8681,UNCHANGED,Covered Recipient Teaching Hospital,,360137.0,10389.0,Uh Cleveland Medical Center,,,,,,,11100 EUCLID AVE,,CLEVELAND,OH,44106,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,240207.0,1306820717.0,SANJAY,P.,AHUJA,,11100 Euclid Ave Stop 6054,,Cleveland,OH,44106,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pediatrics|Pediatric Hematology-Oncology,,,,,,OH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sanofi and Genzyme US Companies,100000000297,GENZYME CORPORATION,MA,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12562.11,12/06/2021,Cash or cash equivalent,,,,,,,No,No,"ATLAS-PEDS: An Open-label, Multinational Study of Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B",No,838665153,2021,01/20/2023,NCT03974113,,
3141,UNCHANGED,Covered Recipient Teaching Hospital,,210056.0,10693.0,Good Samaritan Hospital,,,,,,,5601 Loch Raven Blvd,,Baltimore,MD,21239,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,299243.0,1609074038.0,MAHSA,,MOHEBTASH,,201 E UNIVERSITY PKWY,201 E UNIVERSITY PKWY,BALTIMORE,MD,21218-2829,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,MD,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Merck Sharp & Dohme Corporation,100000000053,Merck Sharp & Dohme Corporation,NJ,United States,Yes,Covered,Biological,ONCOLOGY,KEYTRUDA,0006-3029-02,,Covered,Biological,ONCOLOGY,LYNPARZA,0310-0657-58,,,,,,,,,,,,,,,,,,,,13959.02,12/31/2021,In-kind items and services,,,,,,,No,No,"A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer",No,848754817,2021,01/20/2023,,,
1898,UNCHANGED,Covered Recipient Teaching Hospital,,54009.0,11327.0,Resnick Neuropsychiatric Hospital At,,,,,,,150 UCLA MEDICAL PLAZA,,LOS ANGELES,CA,90095,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,233526.0,1144286162.0,DAWN,S.,ELIASHIV,,100 MEDICAL PLZ,MC 176919,LOS ANGELES,CA,90095-0001,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology,,,,,,CA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NEUROPACE, INC.",100000010697,"NEUROPACE, INC.",CA,United States,Yes,Covered,Device,Epilepsy,RNS System,,00855547005267,,,,,,,,,,,,,,,,,,,,,,,,,425.0,07/12/2021,Cash or cash equivalent,,,,,,,No,No,Post Approval Study,No,851400757,2021,01/20/2023,,,
3091,UNCHANGED,Covered Recipient Teaching Hospital,,140010.0,10431.0,Northshore University Healthsystem,,,,,,,2650 Ridge Ave,,Evanston,IL,60201,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,376100.0,1457528101.0,LIANA,K,BILLINGS,,9977 WOODS DR,STE 300,SKOKIE,IL,60077,United States,,,Medical Doctor,,,,,,"Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism",,,,,,IL,MA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,Denmark,Yes,Non-Covered,Drug,Diabetes,,,,,,,,,,,,,,,,,,,,,,,,,,,,15.9,09/03/2021,In-kind items and services,,,,,,,No,No,EX9536-4388,No,810797484,2021,01/20/2023,,,
3248,UNCHANGED,Covered Recipient Teaching Hospital,,100009.0,10836.0,University Of Miami Hospital,,,,,,,1400 NW 12TH AVE,,MIAMI,FL,33136,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1238846.0,1750517959.0,JUSTIN,,WATTS,,1120 NW 14TH ST,# 1182,MIAMI,FL,33136,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,FL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Incyte Corporation,100000000263,Incyte Corporation,DE,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8934.0,04/09/2021,Cash or cash equivalent,,,,,,,No,No,"A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis",No,831101479,2021,01/20/2023,,,"Payments or transfers of value related to research are provided to a studys respective site and associated, per CMS requirements, with a Principal Investigator. The amount of this record may be associated with a payment or it may be associated with other transfers of value related to research, including, but not limited to, service costs, supplies, equipment and rentals, investigator meeting costs, and study drug."
2115,UNCHANGED,Covered Recipient Teaching Hospital,,230046.0,10547.0,UNIV OF MI HOSPITALS & HLTH CTRS,,,,,,,1500 East Medical Center Drive,,Ann Arbor,MI,48105,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1139833.0,1275559882.0,SHOBHA,V,MALVIYA,,1500 E MEDICAL CENTER DR,,ANN ARBOR,MI,48109,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Anesthesiology,,,,,,MI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Pfizer Inc.,100000000286,PFIZER INC.,NY,United States,Yes,Covered,Drug,SEDATIVE,PRECEDEX,0409-1638-02,,,,,,,,,,,,,,,,,,,,,,,,,,8527.23,02/24/2021,Cash or cash equivalent,,,,,,,No,No,A PHASE 34 RANDOMIZED DOUBLEBLIND DOSERANGING STUDY OF THE SAFETY AND EFFICACY OF DEXMEDETOMIDINE DEX USED WITH PROPOFOL PRO AS NEEDED FOR PROCEDURAL SEDATION OF PEDIATRIC SUBJECTS 1 MONTH TO 17 YEARS OF AGE UNDERGOING MRI SCANS,No,832764411,2021,01/20/2023,,,
2678,UNCHANGED,Covered Recipient Teaching Hospital,,50262.0,11328.0,Ronald Reagan Ucla,,,,,,,757 Westwood Plaza,,Los Angeles,CA,90095,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,906526.0,1093074106.0,Nicholas,P,McAndrew,,120 S Spalding Dr Ste 401,,Beverly Hills,CA,90212,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,CA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Daiichi Sankyo Inc.,100000000195,Daiichi Sankyo Inc.,NJ,United States,Yes,Covered,Drug,ONCOLOGY,Enhertu,65597-406-01,,,,,,,,,,,,,,,,,,,,,,,,,,29466.0,10/15/2021,Cash or cash equivalent,,,,,,,No,No,DS8201-A-U303,No,835067283,2021,01/20/2023,NCT03734029,,
5913,UNCHANGED,Covered Recipient Physician,,,,,386075.0,1801872510.0,HENRY,KLAR,YAGGI,,300 CEDAR ST  S425A,,NEW HAVEN,CT,06519,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease,,,,,,CT,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Pfizer Inc.,100000000286,PFIZER INC.,NY,United States,Yes,Covered,Drug,CARDIOVASCULAR,STEGLATRO,0006-5363-03,,,,,,,,,,,,,,,,,,,,,,,,,,1900.0,10/22/2021,In-kind items and services,,,,,,,No,No,ERTUGLIFLOZIN CLINICAL PUBLICATION PROGRAM,No,832534329,2021,01/20/2023,,,No payment was made directly to this author. This is a fair market value payment for editorial or medical writing services paid to a 3rd-party vendor to assist with the development of a publication.
7308,UNCHANGED,Covered Recipient Teaching Hospital,,360180.0,10373.0,Cleveland Clinic Hospital,,,,,,,9500 Euclid Ave,,Cleveland,OH,44195,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1294466.0,1811284458.0,Shrif,Joseph,Costandi,,9500 Euclid Ave,,Cleveland,OH,44195-0001,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine,,,,,,OH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Vertos Medical, Inc.",100000016247,"Vertos Medical, Inc.",CA,United States,Yes,Covered,Device,Orthopedic,mild Device Kit,,B235MDK00010,,,,,,,,,,,,,,,,,,,,,,,,,6359.0,05/06/2021,Cash or cash equivalent,,,,,,,No,No,The MOTION Study,No,841915017,2021,01/20/2023,NCT03610737,,
63,UNCHANGED,Covered Recipient Teaching Hospital,,160058.0,10604.0,University Of Iowa Hosp & Clinics,,,,,,,200 Hawkins Dr,,Iowa City,IA,52242,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1224086.0,1235421140.0,MARCELO,L,CORREIA,,200 HAWKINS DR,# 2857,IOWA CITY,IA,52242,United States,,,Medical Doctor,,,,,,"Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism",,,,,,IA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,Denmark,Yes,Covered,Drug,Obesity,Wegovy,0169-4525-14,,,,,,,,,,,,,,,,,,,,,,,,,,56.9,04/22/2021,In-kind items and services,,,,,,,No,No,EX9536-4388,No,811672853,2021,01/20/2023,,,
2380,UNCHANGED,Covered Recipient Teaching Hospital,,230019.0,10502.0,PROVIDENCE HOSPITAL,,,,,,,47601 Grand River Ave,,Novi,MI,48374,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,182837.0,1033367362.0,HERMAN,S,KADO,,28625 NORTHWESTERN HWY,SUITE 150,SOUTHFIELD,MI,48034-1828,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease,,,,,,MI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Inari Medical, Inc.",100000121364,"Inari Medical, Inc.",CA,United States,Yes,Covered,Device,VTE,"FLOWTRIEVER CATHETER, S",,00850291007000,,,,,,,,,,,,,,,,,,,,,,,,,207.69,03/15/2021,Cash or cash equivalent,,,,,,,No,No,FLOWTRIEVER ALL-COMER REGISTRY FOR PATIENT SAFETY AND HEMODYNAMICS (FLASH),No,850616171,2021,01/20/2023,NCT03761173,,
7744,UNCHANGED,Covered Recipient Teaching Hospital,,310001.0,10178.0,Hackensack University Medical Center,,,,,,,30 Prospect Ave,,Hackensack,NJ,07601,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1300461.0,1023277910.0,NOA,,BIRAN,,92 2ND ST,,HACKENSACK,NJ,07601-2191,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,NJ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Janssen Research & Development, LLC",100000005592,"Janssen Research & Development, LLC",NJ,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1670.0,10/05/2021,Cash or cash equivalent,,,,,,,No,No,A Multiarm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants with Multiple Myeloma,No,787582651,2021,01/20/2023,,,
2125,UNCHANGED,Covered Recipient Teaching Hospital,,410012.0,10006.0,THE MIRIAM HOSPITAL,,,,,,,164 Summit Ave,,Providence,RI,02906,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,5112.0,1114988243.0,ADAM,,KLIPFEL,,208 COLLYER ST,SUITE,PROVIDENCE,RI,02904-1560,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Colon & Rectal Surgery,,,,,,MA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000337,"Takeda Pharmaceuticals U.S.A., Inc.",IL,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,35644.0,02/25/2021,Cash or cash equivalent,,,,,,,No,No,"A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EFFICACY AND SAFETY OF CX601, ADULT ALLOGENEIC EXPANDED ADIPOSE-DERIVED STEM CELLS (EASC) FOR THE TREATMENT OF COMPLEX PERIANAL FISTULA(S) IN PATIENTS WITH CROHN'S DISEASE OVER A PERIOD OF 24 WEEKS AND A FOLLOW-UP PERIOD UP TO 52 WEEKS",No,816667137,2021,01/20/2023,NCT03279081,,
3973,UNCHANGED,Covered Recipient Teaching Hospital,,340091.0,10794.0,The Moses H. Cone Memorial Hospital,,,,,,,1200 N ELM ST,,GREENSBORO,NC,27401,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,647391.0,1972560894.0,PRAMOD,P.,SETHI,,912 3rd St,Ste 101,Greensboro,NC,27405,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology,,,,,,NC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,United States,Yes,Covered,Device,Cardiac Diagnostics and Monitoring,Reveal LINQ,,00643169845749,,,,,,,,,,,,,,,,,,,,,,,,,3840.0,10/11/2021,Cash or cash equivalent,,,,,,,No,No,Stroke AF,No,801009931,2021,01/20/2023,,,
7695,UNCHANGED,Covered Recipient Teaching Hospital,,100271.0,10837.0,MOFFITT CANCER CENTER,,,,,,,12902 Magnolia Dr,,Tampa,FL,33612,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,235583.0,1194758805.0,NIKHIL,I,KHUSHALANI,,ELM AND CARLTON ST,,BUFFALO,NY,14263-0001,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,,,,,,FL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Regeneron Pharmaceuticals, Inc.",100000000069,"Regeneron Pharmaceuticals, Inc.",NY,United States,Yes,Covered,Biological,ONCOLOGY,LIBTAYO,61755-008-01,,,,,,,,,,,,,,,,,,,,,,,,,,105.0,10/21/2021,Cash or cash equivalent,,,,,,,No,No,A PHASE 2 STUDY OF NEOADJUVANT CEMIPLIMAB FOR STAGE II TO IV (M0) CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC),No,793088387,2021,01/20/2023,NCT04154943,,
2595,UNCHANGED,Covered Recipient Teaching Hospital,,330285.0,10135.0,Strong Memorial Hospital,,,,,,,601 Elmwood Ave,,Rochester,NY,14642,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,10251992.0,1588050587.0,EMILY,D,CLARK,,601 Elmwood Ave,,Rochester,NY,14642-0001,United States,,,Doctor of Osteopathy,,,,,,Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Geriatric Psychiatry,,,,,,NY,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Biogen, Inc.",100000000193,"Biogen, Inc.",MA,United States,Yes,Covered,Biological,NEUROLOGY,ADUHELM,,,,,,,,,,,,,,,,,,,,,,,,,,,145389.0,07/23/2021,Cash or cash equivalent,,,,,,,No,No,"A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205",No,828998839,2021,01/20/2023,,,
2889,UNCHANGED,Covered Recipient Teaching Hospital,,143300.0,10439.0,ANN & ROBERT H. LURIE CHILDRENS HOS,,,,,,,1121 TECHNY RD,,NORTHBROOK,IL,60062,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,596900.0,1215115985.0,RACHEL,GLICK,ROBISON,,3601 THE VANDERBILT CLINIC,,NASHVILLE,TN,37232-2991,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Pediatrics,,,,,,IL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"AIMMUNE THERAPEUTICS, INC.",100000776814,"AIMMUNE THERAPEUTICS, INC.",CA,United States,Yes,Covered,Biological,ALLERGY,PALFORZIA,71881-113-13,,,,,,,,,,,,,,,,,,,,,,,,,,21.42,12/31/2021,Cash or cash equivalent,,,,,,,No,No,PEANUT ORAL IMMUNOTHERAPY STUDY OF EARLY INTERVENTION FOR DESENSITIZATION (POSEIDON),No,849615135,2021,01/20/2023,,,
7131,UNCHANGED,Covered Recipient Teaching Hospital,,280040.0,10660.0,NEBRASKA METHODIST HOSPITAL,,,,,,,8303 Dodge Street,,Omaha,NE,68114,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,111494.0,1457322166.0,YUNGPO,B,SU,,7500 MERCY RD,SUITE 1300,OMAHA,NE,68124-2319,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,NE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Regeneron Pharmaceuticals, Inc.",100000000069,"Regeneron Pharmaceuticals, Inc.",NY,United States,Yes,Covered,Biological,ONCOLOGY,LIBTAYO,61755-008-01,,,,,,,,,,,,,,,,,,,,,,,,,,1000.0,10/26/2021,Cash or cash equivalent,,,,,,,No,No,A PHASE 2 STUDY OF NEOADJUVANT CEMIPLIMAB FOR STAGE II TO IV (M0) CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC),No,793088651,2021,01/20/2023,NCT04154943,,
612,UNCHANGED,Covered Recipient Physician,,,,,545671.0,1417011529.0,ALICIA,K,MORGANS,,676 N SAINT CLAIR ST FL 21,,CHICAGO,IL,60611-2927,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,,,,,,IL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Astellas Pharma Global Development,100000005406,Astellas Pharma Global Development,IL,United States,Yes,Covered,Drug,ONCOLOGY,XTANDI,0469-0125-99,,,,,,,,,,,,,,,,,,,,,,,,,,241.88,12/31/2021,In-kind items and services,,,,,,,No,No,Enzalutamide PSA Post Hoc Analysis,No,831024893,2021,01/20/2023,,,
9383,UNCHANGED,Covered Recipient Teaching Hospital,,340113.0,10768.0,Carolinas Medical Center,,,,,,,1000 Blythe Blvd,32861,Charlotte,NC,28232,United States,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"UCB, Inc.",100000010777,UCB GmbH,,Germany,Yes,Covered,Drug,Immunology,Cimzia,50474-710-79,,,,,,,,,,,,,,,,,,,,,,,,,,1627.2,04/26/2021,Cash or cash equivalent,,,,,,,No,No,"PHASE 3, MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN CHILDREN AND ADOLESCENTS WITH MODERATELY TO SEVERELY ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS",No,844222799,2021,01/20/2023,NCT01550003,,
81,UNCHANGED,Covered Recipient Physician,,,,,303222.0,1679551444.0,BRADLEY,S,GIEDD,,1928 HOWELL BRANCH RD,,WINTER PARK,FL,32792-1013,United States,,,Doctor of Optometry,,,,,,Eye and Vision Services Providers|Optometrist,,,,,,FL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Alcon Research LLC,100000000218,Alcon Research LLC,TX,United States,Yes,Covered,Device,Ophthamology,TOTAL 30,,,,,,,,,,,,,,,,,,,,,,,,,,,354.0,05/05/2021,Cash or cash equivalent,,,,,,,No,No,Clinical Biocompatibility of Three Daily Wear Monthly Replacement Silicone Hydrogel Contact Lenses with Two Multi-purpose Disinfecting Solution Combinations,No,807648565,2021,01/20/2023,,,
5220,UNCHANGED,Covered Recipient Physician,,,,,230474.0,1083766604.0,RAMY,J.,TOMA,,832 Princeton Ave Sw Ste 2,,Birmingham,AL,35211,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine,,,,,,AL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sanofi Pasteur Inc.,100000000299,SANOFI PASTEUR INC.,PA,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1715.0,12/10/2021,Cash or cash equivalent,,,,,,,No,No,Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines With AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Two Monovalent and One Bivalent),No,838359903,2021,01/20/2023,NCT04762680,,
1935,UNCHANGED,Covered Recipient Teaching Hospital,,100271.0,10837.0,MOFFITT CANCER CENTER,,,,,,,12902 Magnolia Dr,,Tampa,FL,33612,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1294667.0,1073707170.0,MIHAELA,,DRUTA,,12902 USF MAGNOLIA DR,,TAMPA,FL,33612-9416,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,,,,,,FL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Deciphera Pharmaceuticals Inc.,100000776815,Deciphera Pharmaceuticals Inc.,MA,United States,Yes,Covered,Drug,ONCOLOGY,QINLOCK,73207-101-31,,,,,,,,,,,,,,,,,,,,,,,,,,312.8,10/16/2021,Cash or cash equivalent,,,,,,,No,No,INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE,No,827886967,2021,01/20/2023,NCT03673501,,
1753,UNCHANGED,Covered Recipient Teaching Hospital,,330204.0,10075.0,BELLEVUE HOSPITAL CENTER,,,,,,,462 1ST AVE,C   D BUILDING RM 342,NEW YORK,NY,10016,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,764459.0,1083772693.0,SHARON,,MANNHEIMER,,506 MALCOLM X BLVD,,NEW YORK,NY,10037,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease,,,,,,NY,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,United States,Yes,Covered,Biological,Immunology,Actemra,50242-137-01,,,,,,,,,,,,,,,,,,,,,,,,,,1000.0,01/26/2021,Cash or cash equivalent,,,,,,,No,No,TOCILIZUMAB THERAPY FOR COVID 19 PNEUMONIA IN HOSPITALIZED PATIENTS,No,835906979,2021,01/20/2023,,,
2014,UNCHANGED,Covered Recipient Teaching Hospital,,220110.0,9985.0,Brigham And Womens Hospital,,,,,,,C/O RESEARCH FINANCE,,BOSTON,MA,02241,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,286283.0,1326006818.0,GREGORY,,PIAZZA,,75 FRANCIS ST,,BOSTON,MA,02115,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|General Practice,,,,,,MA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BOSTON SCIENTIFIC CORPORATION,100000005674,Boston Scientific Corporation,MA,United States,Yes,Non-Covered,Device,Clinical Trial Product,DESBTK,,,,,,,,,,,,,,,,,,,,,,,,,,,1500.0,07/19/2021,Cash or cash equivalent,,,,,,,No,No,KNOCOUT PE,No,800044021,2021,01/20/2023,,,
5963,UNCHANGED,Covered Recipient Physician,,,,,5703942.0,1518283662.0,AMY,LEE,LIGHTNER,,1120 24TH ST APT D,,SANTA MONICA,CA,90403-5815,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|General Practice,,,,,,CA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000337,"Takeda Pharmaceuticals U.S.A., Inc.",IL,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1000.0,02/05/2021,Cash or cash equivalent,,,,,,,No,No,POSTAUTHORIZATION SAFETY STUDY OF THE LONG-TERM SAFETY AND EFFICACY OF REPEAT ADMINISTRATION OF DARVADSTROCEL IN PATIENTS WITH CROHN'S DISEASE AND COMPLEX PERIANAL FISTULA,No,827454783,2021,01/20/2023,NCT04118088,,
4366,UNCHANGED,Covered Recipient Teaching Hospital,,10033.0,10929.0,University Of Alabama Hospital,,,,,,,619 19TH ST S,,BIRMINGHAM,AL,35249,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,1253106.0,1275569014.0,JERZY,,SZAFLARSKI,,222 PIEDMONT AVE STE 3200,,CINCINNATI,OH,45219,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology,,,,,,AL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NEUROPACE, INC.",100000010697,"NEUROPACE, INC.",CA,United States,Yes,Covered,Device,Epilepsy,RNS System,,00855547005267,,,,,,,,,,,,,,,,,,,,,,,,,630.0,09/26/2021,Cash or cash equivalent,,,,,,,No,No,Post Approval Study,No,851397105,2021,01/20/2023,,,
2433,UNCHANGED,Covered Recipient Physician,,,,,65449.0,1447202163.0,RISHI,,GUPTA,,61 Whitcher St Ne,Ste 3110,Marietta,GA,30060,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Neurological Surgery,,,,,,GA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Medtronic, Inc.",100000000106,"Medtronic, Inc.",MN,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,400.0,09/08/2021,Cash or cash equivalent,,,,,,,No,No,ELEVATE Study,No,801013259,2021,01/20/2023,,,
5041,UNCHANGED,Covered Recipient Teaching Hospital,,440015.0,10348.0,University Of Tennessee Medical Cent,,,,,,,1924 Alcoa Hwy,,Knoxville,TN,37920,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,4219198.0,1528293701.0,ANDREW,DAVID,NICHOLSON,,1932 ALCOA HWY STE C360,,KNOXVILLE,TN,37920,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Radiology|Diagnostic Radiology,,,,,,TN,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Penumbra, Inc.",100000010583,"Penumbra, Inc.",CA,United States,Yes,Covered,Device,Neurointervention,Smart Coil,,00814548015286,,,,,,,,,,,,,,,,,,,,,,,,,150.0,09/09/2021,Cash or cash equivalent,,,,,,,No,No,SURF,No,840451451,2021,01/20/2023,,,
6175,UNCHANGED,Covered Recipient Teaching Hospital,,450076.0,11031.0,Ut Md Anderson Cancer Center,,,,,,,1515 HOLCOMBE BLVD,,HOUSTON,TX,77030,United States,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bristol Myers Squibb Company,100000005499,"E.R. Squibb & Sons, L.L.C.",NJ,United States,Yes,Covered,Biological,Oncology,OPDIVO,0003-3774-12,,,,,,,,,,,,,,,,,,,,,,,,,,674.0,04/15/2021,Cash or cash equivalent,,,,,,,No,No,Phase III 1L H&N Metastatic nivo chemo,No,819881955,2021,01/20/2023,,,
8865,UNCHANGED,Covered Recipient Teaching Hospital,,220162.0,9984.0,DANA-FARBER CANCER INSTITUTE,,,,,,,450 Brookline Ave,,Boston,MA,02215,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,817811.0,1972762326.0,ISABEL,C,ARRILLAGA-ROMANY,,MASSACHUSETTS GENERAL HOSPITAL,55 FRUIT STREET,BOSTON,MA,02114,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology,,,,,,MA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Servier Pharmaceuticals LLC,100000246816,Servier Pharmaceuticals LLC,MA,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,61978.0,09/20/2021,Cash or cash equivalent,,,,,,,No,No,STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO),No,851687951,2021,01/20/2023,NCT04164901,https://clinicaltrials.gov/ct2/show/NCT04164901,
9806,UNCHANGED,Covered Recipient Teaching Hospital,,30087.0,11159.0,HONORHEALTH SCOTTSDALE SHEA MED CTR,,,,,,,9003 E SHEA BLVD,,SCOTTSDALE,AZ,85260,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,277405.0,1114929114.0,MICHAEL,S,GORDON,,9055 E DEL CAMINO DR,SUITE 100,SCOTTSDALE,AZ,85258,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,AZ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,United States,Yes,Covered,Biological,BioOncology,TECENTRIQ,50242-917-01,,Non-Covered,Drug,,,,,,,,,,,,,,,,,,,,,,,1185.0,09/16/2021,Cash or cash equivalent,,,,,,,No,No,A PHASE IA IB OPEN LABEL DOSE ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XMAB24306 ALO,No,835913509,2021,01/20/2023,,,
5204,UNCHANGED,Covered Recipient Teaching Hospital,,440039.0,10425.0,Vanderbilt University Medical Center,,,,,,,1211 Medical Center Drive,,Nashville,TN,37232,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,409450.0,1629160056.0,MICHAEL,E,MAY,,1215 21ST AVE S,FL 8,NASHVILLE,TN,37232,United States,,,Medical Doctor,,,,,,"Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism",,,,,,TN,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,Denmark,Yes,Covered,Drug,Diabetes,RYBELSUS,0169-4303-13,,,,,,,,,,,,,,,,,,,,,,,,,,6.72,03/11/2021,In-kind items and services,,,,,,,No,No,EX9924-4473,No,811858275,2021,01/20/2023,,,
9676,UNCHANGED,Covered Recipient Teaching Hospital,,160058.0,10604.0,University Of Iowa Hosp & Clinics,,,,,,,200 HAWKINS DR,,IOWA CITY,IA,52242,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,825763.0,1255316303.0,DANA,M.,KING,,200 HAWKINS DR,,IOWA CITY,IA,52242-1009,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Emergency Medicine|Emergency Medical Services,,,,,,IA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Alexion Pharmaceuticals, Inc.",100000005462,"Alexion Pharmaceuticals, Inc.",MA,United States,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,29743.38,12/22/2021,Cash or cash equivalent,,,,,,,No,No,A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa Inhibitor,No,781384353,2021,01/20/2023,NCT03661528,,
7951,UNCHANGED,Covered Recipient Teaching Hospital,,390111.0,10224.0,Hospital Of The Univ Of Penna,,,,,,,3701 MARKET ST,,PHILA,PA,19104,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,212120.0,1679503783.0,HOWARD,C.,HERRMANN,,3400 Civic Center Blvd Fl 2,,Philadelphia,PA,19104,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology,,,,,,PA,,,,,Covered Recipient Physician,237949.0,1235186073.0,JOSEPH,E.,BAVARIA,,3400 Civic Center Blvd,,Philadelphia,PA,19104,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Thoracic Surgery (Cardiothoracic Vascular Surgery),,,,,,PA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Edwards Lifesciences Corporation,100000010633,Edwards Lifesciences Corporation,CA,United States,Yes,Covered,Device,Transcatheter Heart Valves,EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV),,00690103194357,,,,,,,,,,,,,,,,,,,,,,,,,72900.01,02/11/2021,Cash or cash equivalent,,,,,,,No,No,Partner3 2015-08,No,809685397,2021,01/20/2023,,,
7990,UNCHANGED,Covered Recipient Teaching Hospital,,220071.0,9988.0,Massachusetts General Hospital,,,,,,,55 Fruit Street,,Boston,MA,02114,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,222771.0,1902896087.0,Jeremy,,Goverman,,55 Fruit St,,Boston,MA,02114-2621,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Surgery|Surgical Critical Care,,,,,,MA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Medline Industries, Inc.",100000005431,"Medline Industries, Inc.",IL,United States,Yes,Covered,Device,Dermatology/Wound Care,Skin Harvesting System,,10080196674039,Covered,Medical Supply,Dermatology/Wound Care,Art Disposables,,10193489007114,,,,,,,,,,,,,,,,,,,25620.0,10/13/2021,In-kind items and services,,,,,,,No,No,A Prospective Pilot Study on the Use of Full Thickness Micro Skin Tissue Columns in Burn Care,No,849336959,2021,01/20/2023,,,
2182,UNCHANGED,Covered Recipient Teaching Hospital,,330154.0,10065.0,Memorial Hospital For Cancer And All,,,,,,,1275 York Avenue,,New York,NY,10065,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,789835.0,1972769800.0,VICKY,,MAKKER,,1275 YORK AVENUE,,NEW YORK,NY,10065,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,NY,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Eisai Inc.,100000000136,Eisai Inc.,NJ,United States,Yes,Covered,Drug,Oncology,Lenvima,62856-710-30,,,,,,,,,,,,,,,,,,,,,,,,,,3156.65,11/01/2021,Cash or cash equivalent,,,,,,,No,No,"A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors",No,836180329,2021,01/20/2023,,,
6107,UNCHANGED,Covered Recipient Teaching Hospital,,50146.0,11296.0,CITY OF HOPE NATIONAL MEDICAL CTR,,,,,,,1500 E Duarte Rd,,Duarte,CA,91010,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,701485.0,1861692485.0,IBRAHIM,T,ALDOSS,,1500 E DUARTE RD,DEPARTMENT OF HEMATOLOGY & HCT,DUARTE,CA,91010-3012,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology,,,,,,CA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Takeda Pharmaceuticals U.S.A., Inc.",100000000337,"Takeda Pharmaceuticals U.S.A., Inc.",IL,United States,Yes,Covered,Drug,ONCOLOGY,ICLUSIG,63020-535-30,,,,,,,,,,,,,,,,,,,,,,,,,,2435.0,02/17/2021,Cash or cash equivalent,,,,,,,No,No,"A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY COMPARING PONATINIB VERSUS IMATINIB, ADMINISTERED IN COMBINATION WITH REDUCED-INTENSITY CHEMOTHERAPY, IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL)",No,816652477,2021,01/20/2023,NCT03589326,,
4717,UNCHANGED,Covered Recipient Teaching Hospital,,100271.0,10837.0,Moffitt Cancer Center,,,,,,,12902 Magnolia Dr,,Tampa,FL,33612,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,709029.0,1124227780.0,JINGSONG,,ZHANG,,12902 USF MAGNOLIA DR,H LEE MOFFITT CANCER CENTER,TAMPA,FL,33612,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology,,,,,,FL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Exelixis Inc.,100000010545,Exelixis Inc.,CA,United States,Yes,Covered,Drug,Oncology,CABOMETYX,42388-023-26,,,,,,,,,,,,,,,,,,,,,,,,,,532.0,07/02/2021,Cash or cash equivalent,,,,,,,No,No,Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,No,838853679,2021,01/20/2023,NCT03170960,,
9454,UNCHANGED,Covered Recipient Teaching Hospital,,150048.0,10409.0,Reid Hospital & Health Care Services,,,,,,,1401 Chester Boulevard,,Richmond,IN,47374,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,676885.0,1003845371.0,JOHN,EDWARD,MCGINTY,IV,1100 REID PKWY,SUITE 210,RICHMOND,IN,47374-1157,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease,,,,,,IN,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Boehringer Ingelheim USA, Inc.",100000005541,Boehringer Ingelheim International GmbH,,Germany,Yes,Covered,Drug,DIABETES,JARDIANCE,0597-0152-30,,,,,,,,,,,,,,,,,,,,,,,,,,78.67,03/03/2021,In-kind items and services,,,,,,,No,No,Empagliflozin and heart failure (HFpEF),No,828341205,2021,01/20/2023,,,
971,UNCHANGED,Covered Recipient Teaching Hospital,,490009.0,10745.0,University Of Virginia Medical Cente,,,,,,,1215 Lee St Pfs,,Charlottesville,VA,22908,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,768804.0,1235390444.0,RYAN,D,GENTZLER,,1240 LEE ST,,CHARLOTTESVILLE,VA,22908,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,VA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,AstraZeneca Pharmaceuticals LP,100000010370,AstraZeneca UK Limited,,Great Britain (Uk),Yes,Covered,Drug,Oncology,TAGRISSO,0310-1349-30,,,,,,,,,,,,,,,,,,,,,,,,,,51038.0,07/27/2021,Cash or cash equivalent,,,,,,,No,No,An observational cohort linkage study from the Danish Lung Cancer Registry and Danish Pathology Registry to describe prevalence of EGFR mutations treatment and outcomes in stage I-IIIA lung cancer,No,826469445,2021,01/20/2023,,,
7260,UNCHANGED,Covered Recipient Teaching Hospital,,30087.0,11159.0,HONORHEALTH SCOTTSDALE SHEA MED CTR,,,,,,,9003 E SHEA BLVD,,SCOTTSDALE,AZ,85260,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,201693.0,1447239231.0,BARRY,A,HENDIN,,3805 E BELL RD,,PHOENIX,AZ,85032,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology,,,,,,AZ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Genentech, Inc.",100000005656,F. Hoffmann-La Roche AG,,Switzerland,Yes,Covered,Biological,Immunology,OCREVUS,50242-150-01,,Non-Covered,Drug,,,,,,,,,,,,,,,,,,,,,,,39048.0,09/14/2021,Cash or cash equivalent,,,,,,,No,No,SECOND PHASE III IN RMS,No,835913581,2021,01/20/2023,,,
5186,UNCHANGED,Covered Recipient Physician,,,,,30973.0,1679558027.0,GIL,,YOSIPOVITCH,,1295 NW 14TH ST STE KL,,MIAMI,FL,33125,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Dermatology,,,,,,FL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Pfizer Inc.,100000000286,PFIZER INC.,NY,United States,Yes,Covered,Drug,GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT,XELJANZ,0069-1001-01,,,,,,,,,,,,,,,,,,,,,,,,,,780.0,11/29/2021,In-kind items and services,,,,,,,No,No,TOFACITINIB CLINICAL PUBLICATION PROGRAM,No,832534299,2021,01/20/2023,,,No payment was made directly to this author. This is a fair market value payment for editorial or medical writing services paid to a 3rd-party vendor to assist with the development of a publication.
1291,UNCHANGED,Covered Recipient Teaching Hospital,,50040.0,11320.0,Lac Olive View/Ucla Medical Center,,,,,,,14445 Olive View Dr,,Sylmar,CA,91342,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,127894.0,1811967433.0,MATTHEW,J,BUDOFF,,1000 W CARSON ST,STE 700,TORRANCE,CA,90502,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease,,,,,,CA,WI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Novo Nordisk AS,100000000163,Novo Nordisk AS,,Denmark,Yes,Non-Covered,Drug,Diabetes,,,,,,,,,,,,,,,,,,,,,,,,,,,,56.9,05/20/2021,In-kind items and services,,,,,,,No,No,EX9536-4388,No,811320015,2021,01/20/2023,,,
8382,UNCHANGED,Covered Recipient Physician,,,,,239967.0,1285634105.0,ROBERT,CHARLES,SERGOTT,,840 WALNUT ST,,PHILADELPHIA,PA,19107,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Ophthalmology|Neuro-ophthalmology,,,,,,DE,NJ,PA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Genentech, Inc.",100000005656,F. Hoffmann-La Roche AG,,Switzerland,Yes,Covered,Biological,Immunology,Enspryng,50242-007-01,,,,,,,,,,,,,,,,,,,,,,,,,,660.91,07/15/2021,In-kind items and services,,,,,,,No,No,"EFFICACY AND SAFETY STUDY AS ADD-ON THERAPY OF SATRALIZUMAB SA237 TO TREAT NMO AND NMOSD, A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NMO SPECTRUM DISORDER NMOSD",No,835903937,2021,01/20/2023,,,Transfer of value reported under this transaction represents publication support services and does not reflect any actual monetary transfer of value to the physician
4367,UNCHANGED,Covered Recipient Teaching Hospital,,450076.0,11031.0,UT MD ANDERSON CANCER CENTER,,,,,,,1515 Holcombe Blvd,,Houston,TX,77030,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,195883.0,1316045008.0,JOHN,F,DE GROOT,,1515 HOLCOMBE BLVD,,HOUSTON,TX,77030-4009,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Clinical Neurophysiology,,,,,,CA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Servier Pharmaceuticals LLC,100000246816,Servier Pharmaceuticals LLC,MA,United States,Yes,Non-Covered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9846.0,04/12/2021,Cash or cash equivalent,,,,,,,No,No,STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO),No,851688553,2021,01/20/2023,NCT04164901,https://clinicaltrials.gov/ct2/show/NCT04164901,
9506,UNCHANGED,Covered Recipient Teaching Hospital,,360068.0,10396.0,The Toledo Hospital,,,,,,,2142 N COVE BLVD,,TOLEDO,OH,43606,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,70978.0,1568487726.0,MARK,,RICHARDS,,2940 N MCCORD RD,,TOLEDO,OH,43615,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Clinical Cardiac Electrophysiology,,,,,,ID,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BIOTRONIK INC.,100000010579,BIOTRONIK INC.,OR,United States,Yes,Covered,Device,Cardiology/Vascular Diseases,Sentus,,04035479148942,Covered,Device,Cardiology/Vascular Diseases,Plexa,,04035479140014,Covered,Device,Cardiology/Vascular Diseases,Acticor,,04035479156701,Covered,Device,Cardiology/Vascular Diseases,Solia,,4035479118266.0,Covered,Device,Cardiology/Vascular Diseases,Rivacor,,4035479156794.0,355.0,03/09/2021,Cash or cash equivalent,,,,,,,No,No,BIO-LIBRA,No,843823029,2021,01/20/2023,,,
7153,UNCHANGED,Covered Recipient Teaching Hospital,,50146.0,11296.0,CITY OF HOPE NATIONAL MEDICAL CTR,,,,,,,1500 E Duarte Rd,,Duarte,CA,91010,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,156689.0,1467408948.0,TANYA,,SIDDIQI,,1500 E DUARTE ROAD,CITY OF HOPE MEDICAL CENTER,DUARTE,CA,91010,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology,,,,,,CA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Pharmacyclics LLC, an AbbVie Company",100000136439,"Pharmacyclics LLC, An AbbVie Company",CA,United States,Yes,Covered,Drug,ONCOLOGY,IMBRUVICA,57962-420-28,,,,,,,,,,,,,,,,,,,,,,,,,,417.6,03/05/2021,Cash or cash equivalent,,,,,,,No,No,Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma,No,786502155,2021,01/20/2023,NCT02910583,,PCYC-1142-CA
2343,UNCHANGED,Covered Recipient Physician,,,,,15451.0,1326200569.0,DANIEL,PABLO,FRIEDMANN,,8825 BEE CAVES RD STE 100,,AUSTIN,TX,78746-4721,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Dermatology|Procedural Dermatology,,,,,,TX,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ABBVIE INC.,100000000204,ABBVIE INC.,IL,United States,Yes,Covered,Biological,FACIAL AESTHETICS,BOTOX,0023-1145-01,,,,,,,,,,,,,,,,,,,,,,,,,,180.57,09/17/2021,In-kind items and services,,,,,,,No,No,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of OnabotulinumtoxinA X for the Treatment of Moderate to Severe Glabellar Lines",No,792403527,2021,01/20/2023,NCT05100199,,2042-201-008
3201,UNCHANGED,Covered Recipient Teaching Hospital,,110087.0,10799.0,NORTHSIDE HOSPITAL GWINNETT,,,,,,,3620 HOWELL FERRY ROAD,,DULUTH,GA,30096,United States,,,,,,,,,,,,,,,,,,,,Covered Recipient Physician,281827.0,1205875218.0,RONALD,,STEIS,,1505 NORTHSIDE BLVD,1500,CUMMING,GA,30041,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology,,,,,,GA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Genentech, Inc.",100000000089,"Genentech, Inc.",CA,United States,Yes,Non-Covered,Drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,229.2,03/01/2021,Cash or cash equivalent,,,,,,,No,No,PH 2 RANDOMIZED POC STUDY OF PCV IN 1L MELANOMA,No,835920973,2021,01/20/2023,,,
6445,UNCHANGED,Covered Recipient Physician,,,,,279584.0,1154398642.0,LALE,,KOSTAKOGLU SHIELDS,,1215 LEE ST,,CHARLOTTESVILLE,VA,22908,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Radiology|Nuclear Radiology,,,,,,NY,VA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Genentech, Inc.",100000005656,F. Hoffmann-La Roche AG,,Switzerland,Yes,Covered,Biological,BioOncology,GAZYVA,50242-070-01,,,,,,,,,,,,,,,,,,,,,,,,,,634.63,03/31/2021,In-kind items and services,,,,,,,No,No,"A PHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED TRIAL COMPARING THE EFFICACY OF GA101 RO5072759 IN COMBINATION WITH CHOP G-CHOP VERSUS RITUXIMAB AND CHOP R-CHOP IN PREVIOUSLY UNTREATED PATIENTS WITH CD20-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA DLBCL",No,835902147,2021,01/20/2023,,,Transfer of value reported under this transaction represents publication support services and does not reflect any actual monetary transfer of value to the physician
9743,UNCHANGED,Covered Recipient Physician,,,,,1146903.0,1518908995.0,FREDERICK,,UELAND,,800 ROSE ST,MS273,LEXINGTON,KY,40536,United States,,,Medical Doctor,,,,,,Allopathic & Osteopathic Physicians|Obstetrics & Gynecology|Gynecologic Oncology,,,,,,KY,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Genentech, Inc.",100000005656,F. Hoffmann-La Roche AG,,Switzerland,Yes,Covered,Biological,BioOncology,TECENTRIQ,50242-917-01,,,,,,,,,,,,,,,,,,,,,,,,,,184.66,03/31/2021,In-kind items and services,,,,,,,No,No,"A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER",No,835899705,2021,01/20/2023,,,Transfer of value reported under this transaction represents publication support services and does not reflect any actual monetary transfer of value to the physician
